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Abstract 
Airway wall remodelling contributes to decreased lung function in asthma. 
Key features of the remodelling process are thickening of the reticular 
basement membrane, differentiation of fibroblast-like cells with contractile 
properties termed myofibroblasts and sub-epithelial deposition of 
extracellular matrix.The pro-fibrogenic cytokine transforming growth factor-
β2 (TGF-β2) is purported to drive remodelling responses. TGF-β2 may be 
upregulated in asthmatic epithelium, and is secreted by bronchial epithelial 
cells following injury.  
 
In this study significant increases in reticular basement membrane thickening 
and myofibroblast differentiation were identified by histology and 
immunohistochemistry of  mild asthmatic and healthy human bronchial 
biopsy tissue, although no significant differences in TGF-β2 expression were 
identified.  
 
It was hypothesised that the proteolytic action of house dust mite (HDM) 
allergens would lead to increased activation of latent TGF-β2 secreted by 
bronchial epithelial cells. A transformed cell line, 16HBE14o-, did not show 
increased activation or expression following HDM extract challenge, however 
TGF-β2 activation and expression was increased following exposure of 
primary human bronchial epithelial cells to a HDM extract.  
 
Myofibroblast differentiation and matrix deposition by healthy and mild 
asthmatic- derived primary bronchial fibroblasts were assessed by α-smooth 
muscle actin expression and soluble collagen production, following challenge 
with exogenous TGF-β2. Results presented here show asthmatic bronchial 
fibroblasts are more sensitive to the myofibroblast priming effects of TGF-β2. 
Bronchial epithelial cell conditioned media challenge of healthy fibroblasts led 
to greater increases in matrix deposition and myofibroblast differentiation 
than was attributable to TGF-β2, with greatest increases seen following 
asthmatic epithelial cell conditioned media exposure. Responses were greater 
than suggested by the epithelial TGF-β2 levels, so it is suggested that 
additional  soluble mediators play a part in airway wall remodelling responses. 
Further work is required to identify the soluble mediators secreted by 
bronchial epithelial cells that control the responses of the underlying 
fibroblasts.  
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Degree: PhD Medicine (Translational Medicine) 
 
Thesis Title: In vitro investigations of Transforming Growth 
Factor-β2 induced airway wall remodelling.  
 
Jan. 2011 
 Gaynor A. Campbell 
  12 
 
Declaration 
No portion of the work referred to has been submitted in support of an 
application for another degree or qualification of this or any other university 
or other institute of learning. 
 
 
Copyright Statement 
 
i. The author of this thesis (including any appendices and/or schedules to this 
thesis) owns any copyright in it (the “Copyright”) and s/he has given The 
University of Manchester the right to use such Copyright for any 
administrative, promotional, educational and/or teaching purposes. 
 
ii. Copies of this thesis, either in full or in extracts, may be made only in  
accordance with the regulations of the John Rylands University Library of  
Manchester.  Details of these regulations may be obtained from the Librarian.  
This page must form part of any such copies made.    
 
iii. The ownership of any patents, designs, trade marks and any and all other 
intellectual property rights except for the Copyright (the “Intellectual Property 
Rights”) and any reproductions of copyright works, for example graphs and 
tables (“Reproductions”), which may be described in this thesis, may not be 
owned by the author and may be owned by third parties.  Such Intellectual 
Property Rights and Reproductions cannot and must not be made available for 
use without the prior written permission of the owner(s) of the relevant 
Intellectual Property Rights and/or Reproductions.  
 
iv. Further information on the conditions under which disclosure, publication 
and commercialisation of this, the Copyright and any Intellectual Property 
Rights and/or Reproductions described in it may take place is available in the 
University IP Policy (see 
http://www.campus.manchester.ac.uk/medialibrary/policies/intellectual-
property.pdf), in any relevant thesis restriction declarations deposited in the 
University Library, The University Library’s regulations (see 
http://www.manchester.ac.uk/library/aboutus/regulations) and in The 
University’s policy on presentation of Theses.  
 
 
 
 
 Gaynor A. Campbell 
  13 
Acknowledgements 
 
I am grateful to my supervisors Dr. Sarah Herrick and Dr. Robin Gore for the 
opportunity to undertake this project.  
 
To others at Manchester for your science chats and assistance in making sense 
of it all- thanks! Especially to Sue Shawcross for PCR chats. And of course Dr. 
Ceri Harrop, who helped me plan fibroblast and epithelial experiments a-
plenty over cake and coffee! 
 
I would like to extend the biggest thankyou in the world to Mum and Dad 
Campbell, for always providing the right sort of encouragement, a haven to 
return to and pennies when being a student made me just too poor. Not 
forgetting my darling sister Eilidh, and the tooties Megan & Donnie, who all 
together never fail to make me smile! 
 
 
 
 
 
 
 Gaynor A. Campbell 
  14 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Dedication 
For Dad Campbell, who taught me how to eat the whale… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Gaynor A. Campbell 
  15 
Chapter 1: Introduction 
 
1.1     Asthma 
Asthma is a disorder of the lung characterised by inflammation, over-
production of mucus and bronchial smooth muscle contraction. It was 
previously thought that asthma was a condition of episodic broncho-
constriction with a remitting pathology, however it is clear that both acute and 
chronic inflammatory responses occur, alongside extensive structural changes 
in the conducting airway wall. The structural changes are collectively termed 
airway wall remodelling (AWR), and evidence suggests AWR may precede the 
development, and thereby diagnosis, of asthma (Bush, 2008; Cohn et al., 
2004).  
 
Investigations of disease heterogeneity show asthma is not a single entity 
differing in severity, but an overlapping range of phenotypes with divergent 
measures of inflammation, allergic stimulation, cell-type involvement and 
airway remodelling. These features contribute to airway hyperresponsiveness 
(AHR) and decreases in lung function  (Holgate and Polosa, 2006). 
  
Pharmacological intervention focuses on relief of asthma symptoms and 
reduction of underlying inflammation. In recent years new treatments have 
been developed directed at reducing or blockading known originators of acute 
asthmatic episodes such as IgE and IL-5. Treatments do not target airway wall 
remodelling, and much remains unknown regarding how remodelling 
phenomena are initiated and maintained, and their contribution to disease 
morbidity.  
 
1.1.1  Asthma prevalence and symptoms 
Asthma affects 300 million people worldwide, including 5.4 million sufferers 
in the UK requiring NHS treatment costing an estimated £996 million in 2009 
(AsthmaUK, 2010). Asthma can be defined as widespread variable airflow 
obstruction that is often reversible (GINA, 2010). Asthma symptoms include, 
 Gaynor A. Campbell 
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but are not limited to, cough, wheeze and shortness of breath, which can be 
both acute and chronic. Often symptoms occur with diurnal variation, and 
severity of symptoms is increased in the early hours of the morning. Airway or 
bronchial hyper-responsiveness (AHR/BHR), whereby an abnormal degree of 
airway narrowing occurs following inhaled exposure to a bronchoconstrictor, 
is an important indicator of asthma. Pathological hallmarks of asthma are 
limited to regions of the conducting airways: the bronchi and bronchioles. 
 
1.1.2  Asthma diagnosis and treatment 
A diagnosis of asthma is made by a clinician following consideration of 
numerous factors including patient history, symptoms and triggers, in 
conjunction with pulmonary function tests. Measurements of forced 
expiratory volume in one second (FEV1) and peak expiratory flow (PEF), 
typically show decreased values in comparison to healthy individuals and are 
characteristically variable (BTS, 2008). Variability can indicate poor disease 
management or difficult disease. Analysis of severe asthma patient 
characteristics has identified four subclinical phenotypes of asthma: 
eosinophilic inflammation positive and eosinophilic inflammation negative, 
subdivided into Th2-cytokine high and Th2-cytokine low (Bradding and 
Green, 2009). 
 
Disease management can require a number of treatments. For the majority of 
asthmatics the condition is well controlled by a combination of β2-
adrenoreceptor antagonists and inhaled glucocorticoids. However, only 70% of 
asthmatics respond to glucocorticoids (Mjaanes et al., 2006). This variation in 
response is possibly due to differences in disease phenotype and genetic 
background. A brief description of commonly used treatments follows. 
 
1.1.2.1  β2-adrenoreceptor agonists  
Delivered by inhalation and commonly referred to as β2-agonists, these bind 
β2-adrenergic receptors (β2AR) on airway smooth muscle cells, activating 
downstream signalling pathways that result in relaxation of the muscle 
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thereby reducing bronchoconstriction. β2-agonists can be broadly split into 
long-acting (LABA- up to 12 hours) and short-acting (SABA- 1-2 hours). 
LABAs or SABAs can be used alone as “rescue therapy” during asthma 
exacerbations. The B2AR gene is encoded on chromosomal region 5q31-32 in 
the IL-4 gene cluster, and can be downregulated by repeated exposure to β2-
agonists (Bhatnagar et al., 2006). LABAs plus inhaled glucocorticoids act 
synergistically in relief of asthma symtoms.  
 
1.1.2.2  Glucocorticoids  
Inhaled glucocorticoids (GC), also referred to as glucocorticosteroids, 
downregulate inflammation in the asthmatic airway. In severe asthma, a 
course of oral steroids may also be used. Glucocorticoids enter cells by 
diffusion across the cell membrane and bind glucocorticoid receptors (GR) in 
the cytoplasm. The receptor is activated and released from a chaperone 
protein, allowing the GC-GR complex to enter the nucleus and bind to 
glucocorticoid response elements (GRE) and co-activator complexes, exerting 
a direct affect on inflammatory gene transcription (Adcock and Caramori, 
2001). 
 
Glucocorticoids downregulate pro-inflammatory genes through inhibition of 
MAPK signalling via induction of MAPK phosphatase-1 (MKP1), and 
inhibition of NFκB (Barnes and Karin, 1997). This  switches off transcription 
of inflammatory genes, and upregulated transcription of anti-inflammatory 
cytokines such as IL-10 may also occur (Adcock et al., 2004). GC may also 
prevent desensitization to β2-agonists by blocking the downregulation of β2AR 
caused by repeated exposure to β2-agonists (Bhatnagar et al., 2006). 
 
1.1.2.3  Leukotriene receptor antagonists 
Leukotrienes are pro-inflammatory mediators generated from arachidonic 
acid and released by immune cells including eosinophils and neutrophils, and 
by mast cells at degranulation. Leukotriene receptor antagonists (LTRA) act by 
sequestering leukotriene receptors preventing pro-inflammatory leukotrienes 
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including LTC4 and LTD4 from binding. The smooth muscle contraction and 
vascular permeability effected by leukotrienes is thus downregulated. LTRAs 
are now often prescribed in mild-moderate asthma for their dual 
bronchodilatory and anti-inflammatory properties.  
 
1.1.2.4  Monoclonal antibody therapy 
The reductionist approach to new asthma therapies has increasingly led to the 
targeting of individual novel components of the asthmatic disease response. A 
number of monoclonal antibodies have been developed for therapeutic use 
following this approach. 
 
Omalizumab is a murine anti-human IgE monoclonal antibody that binds 
circulating IgE at the Fc region, blocking binding to IgE receptors including 
high-affinity FcεRI. This inhibits binding of IgE to receptors on basophils and 
dendritic cells, and the binding and subsequent cross-linking of IgE on mast 
cells (Clark et al., 2006; D'Amato, 2006). Through this sequestration of free 
circulating IgE the allergic response can be attenuated. This treatment is of 
use in those individuals with persistent allergic asthma that is poorly 
controlled by inhaled glucocorticoids, and is not considered suitable for all 
asthmatics. Other monoclonal antibodies have been trialled including 
mepolizumab, an IL-5 blocking antibody. Although mepolizumab reduced 
numbers of circulating eosinophils, it had limited success in reducing tissue 
eosinophils, and had no effect on asthmatic lung response to inhaled allergen 
challenge (Büttner et al., 2003). 
 
Many trials have produced disappointing results in reduction of asthma 
symptoms and/or number of exacerbations. Current research indicates these 
therapies may show greater efficacy when patients are selected by disease 
phenotype beforehand, to identify those whose disease is at least partially 
mediated by the treatment target. 
 
The therapies described were developed either to provide symptomatic relief 
or resolve inflammation in asthma, and have only limited ability to alter the 
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remodelling response. Long-term treatment with GC shows a reduction in 
remodelling markers in some studies (Hoshino et al., 1998c), however there 
remains an opportunity to identify new targets for manipulation that will alter 
the AWR response.  
 
Airway wall remodelling may occur prior to the development of diagnosable 
asthma, and it is not apparent whether this is a purely protective response or 
contributes to progression and maintenance of the disease state. Alteration of 
AWR could potentially have unintended downstream effects. 
 
Finally, an understanding of how the asthmatic disease is initiated could aid in 
identification of targets that are not limited to relief of symptoms, but instead 
aim to “cure” asthmatic disease.  
 
1.1.3  Asthma initiation 
1.1.3.1  Genetics and Environment 
Given the heterogeneity of asthma as a disease, there is no consensus on what 
precludes disease development. It is generally agreed that a combination of 
genetic and environmental factors act to influence the development of asthma.  
 
In a review of asthma genetics, Weiss et al. excluded genetic association 
studies (where a specific genetic variant is tested for in affected individuals 
versus controls) with less than 300 total subjects as, in a complex trait such as 
asthma, smaller sample sizes are statistically underpowered. The studies that 
remained identified 43 candidate genes, on more than 20 different 
chromosomes, that could be associated with asthma. A number of genes are 
also associated with atopy- a known risk factor for asthma (Weiss et al., 2009). 
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Chromosome Gene 
2q 
CTLA4 
IL1RN 
5q 
IL4 
IL13 
CD14 
IL9 
12q 
IFN-γ 
STAT6 
20p ADAM33 
 
Table 1.1 Chromosomal regions of interest and genes associated with 
asthma (Blumenthal, 2005; Van Eerdewegh et al., 2002; Wills-Karp and Ewart, 
2004). 
 
Around 500 genetic loci in total have been proposed as candidate “asthmatic” 
genes. As asthma is heterogenous and complex so is the genetic background 
and heritability of the disease. Phenotypic variation is however currently 
unlinked to the genome. From the large number of candidate genes identified 
and the low significance of these gene polymorphisms individually, it is 
apparent that asthma is the product of accumulations of genetic 
polymorphisms. It is possible these alone do not induce asthma per se, and 
that gene interactions with environmental stimuli are required to initiate and 
drive disease development. Studies on the environmental effects on asthma 
development are often contradictory, however of interest to this project was 
the finding that house dust mite (HDM) exposure in infancy is a risk factor for 
subsequent asthma development (Huss et al., 2001). 
 
Understanding of allergic sensitisation in the lung and the factors leading to 
subsequent development of asthmatic disease is incomplete, and insufficient 
to identify a definite asthmatic prior to disease manifestation. Characterisation 
of cell behaviour in the time period between sensitisation and overt disease 
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could produce information allowing the targeting of asthma initiators in a 
window of opportunity, thereby precluding further disease development. Until 
that possibility is realised it is important to extend understanding of 
established disease mechanisms to subsequently improve treatment regimens 
for established asthmatic disease. 
 
1.1.3.2  Allergic sensitisation 
Although the mechanisms of asthmatic disease initiation are unclear, 
initiation of an allergic asthmatic response is not. Asthma is a Th2 type 
disease, typified by the production of cytokines interleukin-4 (IL-4), IL-5 and 
IL-13, with immunoglobulin E (IgE) a major initiator of pathophysiology 
(Barnes et al., 2002). Sensitisation to allergen occurs in many asthmatics, with 
allergen exposure often leading to a symptomatic response (Craig, 2010; Tovey 
et al., 1981). Briefly, sensitization occurs when dendritic cells in the mucosal 
lining of the lung take up inhaled antigen and migrate to the lymph nodes, 
where they function as professional antigen-presenting cells with 
costimulatory capacity. Antigen presented to naïve T cells as immunogenic 
peptides, alongside costimulation (via CD86) drives CD4+ T cells down the 
Th2 lineage pathway in asthmatics. When Th2 cells in circulation meet specific 
antigen, cytokines such as IL-4, IL-5 and IL-13 (encoded on chromosomal 
region 5q31-32, also known as the IL-4 gene cluster) are secreted. Genetic 
studies have shown mutations in this region to predispose to the development 
of asthma. IL-13 induces goblet cell differentiation in the airway epithelium 
and promotes AHR (Walter et al., 2001; Wills-Karp et al., 1998). IL-4 
promotes B cell production of IgE and IL-5 promotes eosinophil production 
and recruitment from the bone marrow. Antigen specific IgE produced by B 
cells binds FcεRI receptors on the surface of mast cells. Mast cells are 
normally resident in the respiratory tract; greater numbers may accumulate in 
allergic asthma (Brightling et al., 2002). Cross-linking of FcεRI  by IgE on 
mast cells initiates the acute phase asthmatic response (Section 1.1.4.1). 
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1.1.4   Asthmatic airway inflammation 
Asthmatic exacerbation stimuli are broadly definable as allergenic, 
environmental or mechanical. In the asthmatic airway, the response to these 
stimuli is abnormal and termed AHR. Approximately 90% of asthmatics may 
suffer acute asthmatic episodes triggered by allergen, the remainder being 
induced by environmental or mechanical stimuli. Exercise induced asthma, 
where symptoms are only present following physical exertion, occurs even in 
very fit individuals, whilst those with no history of atopy (the predisposition to 
produce IgE upon low dose protein antigen challenge) can experience wheeze, 
cough and tightening of the chest in response to environmental triggers such 
as sudden air temperature change (moving from warm to cold or cold to warm 
areas) and occupational exposure to chemical agents.  
 
1.1.4.1  The acute phase response 
In allergic asthma inhalation of an offending antigen cross-links specific IgE 
bound to FcεRI receptors on mast cells resident in the respiratory tract. IgE 
cross-linking signals the release of potent granule contents from the mast cell, 
initiating the acute phase response. Histamine and prostaglandins released 
cause smooth muscle contraction and rapidly increase vascular permeability 
leading to bronchoconstriction. 
 
The immediate smooth muscle contraction and increased mucus production 
result in the symptoms experienced by sufferers. Increased vascular 
permeability leads to constriction of the airways by increasing tissue volume. 
It also contributes to the chronicity of inflammation by allowing influx of a 
number of inflammatory mediator cells to the area of injury, namely 
eosinophils, CD4+ TH2 cells, additional mast cells and neutrophils. These cells 
are activated in the cytokine milieu of the injury area and release other factors 
that contribute to the ongoing inflammation. TH2  cell release of IL-3 and GM-
CSF recruits and activate eosinophils, which go on to release further 
inflammatory mediators. A “chronic wound” scenario may result through 
these mechanisms, and thus drive further exacerbations and remodelling 
(Holgate et al., 2004). 
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The acute phase reaction may be followed 6-8 hours later by the late-phase 
response. 
 
1.1.4.2  The late phase response 
This can be attributed to other mediators released by mast cells, such as LTD4 
and TNF-α, and the action of eosinophils and macrophages chemotactically 
attracted to the lung following mast cell degranulation. Some mast cell-derived 
molecules and their primary effects are listed in Table 1.2. The late-phase 
reaction results in a second stage of smooth muscle contraction and sustained 
oedema; in essence a further asthmatic episode. 
 
Effector molecule Effect of release 
Tryptase, Cathepsin G Extracellular matrix remodelling 
Leukotrienes C4, D4, E4 
Smooth muscle contraction 
Inc. vascular permeability 
Inc. mucus production 
IL-4, IL-13 
TH2 response promotion 
Mucus production 
IL-3, IL-5, GM-CSF 
Eosinophil activation 
Inc. eosinophil production 
TNF-α 
Endothelium  activation 
Inc. vascular permeability 
Inc. cytokine production 
Histamine 
Smooth muscle contraction 
Inc. vascular permeability 
 
Table 1.2 Effector molecules released by mast cell activation and their 
major effects.  
 
LABAs are often used as “rescue therapy” during acute asthma attacks, and 
inhaled GC treatment can dampen underlying inflammation. However these 
treatments do not resolve the underlying structural changes attributed to 
AWR processes. 
  
1.1.5  Asthmatic airway wall remodelling 
Airway wall remodelling (AWR) is a complex phenomenon with the significant 
effect of reduction of airway calibre, leading to fixed airflow limitation and 
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AHR (Aysola et al., 2008; James et al., 1989; Mitchell et al., 1998). Thickening 
of the airway wall  has been shown to greatly increase the degree of airway 
narrowing that can occur during an acute asthma attack. Airway thickness 
data collected from post-mortem and surgically resected lungs of normal, 
COPD and severe asthma patients, was used to model increasing airway 
resistance caused by calibre reduction using the Poiseuille equation. This 
equation (ΔP=8lµV/πr4, where ΔP= change in pressure, l= length, µ= gas 
velocity, V= flow and  r= airway radius), equates pressure to laminar flow. 
Using this model, it was demonstrated that small alterations in the airway 
radius (narrowing), led to greatly increased pressure (airway resistance) 
(Bossé et al., 2010; Wiggs et al., 1992). 
 
It is unclear whether remodelling is (partially) driven by the inflammatory 
response, or whether the non-resolving inflammatory response is due in some 
part to AWR. With evidence to suggest remodelling occurs prior to or 
concurrently with the development of airway inflammation, it is possible 
remodelling begins as a protective mechanism (Bush, 2008). Regardless of the 
driving factors, AWR has consequences in bronchial architecture and 
behaviour. AWR should be regarded not only as structural changes, but also as 
alterations in the relationship between and among structural cells and other 
airway constituents.  
 
Pathologically, asthma is broadly restricted to the bronchi and bronchioles, 
which form part of the conducting airway tree. Multiple AWR phenomena 
have been identified, and this review shall focus on those reported in the 
epithelium and underlying fibroblasts in the lamina propria.  
 
1.1.5.1 Epithelium 
The archetypal respiratory epithelium of the bronchi consists of 
pseudostratified, ciliated columnar epithelial cells interspersed by non-ciliated 
mucus-producing goblet cells and small basal cells. The asthmatic epithelium 
is often described as fragile, with biopsy studies suggesting increased epithelial 
shedding and damage in asthmatics (Demoly et al., 1995). Basal cell loss of 
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columnar cell attachments is accompanied by increased EGFR and CD44 
expression, suggesting an active process rather than an artefact of biopsy 
sampling and processing (Lackie et al., 1997; Puddicombe et al., 2000). This is 
supported by the finding of increased Creola bodies (clumps of epithelial cells) 
in BAL fluid from asthmatics compared to control subjects (Montefort et al., 
1992). 
 
Goblet cell hyperplasia has been identified in asthmatic epithelium (Ordoñez 
et al., 2001), and their contribution to mucus hyper-secretion is a factor in 
mucus plugging of the airway seen in fatal asthma (Kuyper et al., 2003). A 
number of other features have been identified in asthmatic epithelium, 
including increased PAR-2 expression (Knight et al., 2001), increased STAT6 
expression (Mullings et al., 2001) and increased Endothelin (Vittori et al., 
1992).  
 
Of relevance to this project are the findings of Chu et al. who demonstrated 
increased TGF-β2 expression in asthmatic biopsy tissue compared to healthy 
(Chu et al., 2004). Segmental allergen challenge led to increased TGF-β2 in 
BAL, although in this study basal levels of TGF-β2 were higher in healthy 
individuals (Batra et al., 2004). This is however indicative of a role for TGF-β2 
in maintaining normal lung homeostasis. There is a correlation between TGF-
β positive epithelium and reticular basement thickness (Vignola et al., 1997) 
Furthermore, the identification of increased phospho-Smad-2 signalling and 
decreased Smad-7 expression in asthmatic epithelium suggests a 
dysregulation of TGF-β responsiveness (Nakao et al., 2002; Sagara et al., 
2002). Decreased Smad-7 expression was inversely correlated to reticular 
basement thickness and AHR.  
 
1.1.5.2 Reticular basement membrane 
Anchoring the epithelium to the underlying connective tissue is the reticular 
basement membrane (RBM). This layer can become thickened in asthma, due 
to increased deposition of ECM molecules including the fibrillar collagens I, 
III and V (Wilson and Li, 1997). Increased RBM thickness has been positively 
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correlated with AHR (Hoshino et al., 1998a) and with frequency of asthma 
attacks (Evans et al., 1999). Treatment with inhaled glucocorticoids can 
reduce RBM thickness (Hoshino et al., 1998c) 
 
Increased deposition of Tenascin-C (Tn-C), collagen III and lumican have 
been described at baseline in asthmatics, that could be subsequently decreased 
by anti-IL-5 treatment or inhaled GC (Flood-Page et al., 2003; Laitinen et al., 
1997). An allergen challenge study of asthmatics identified a significant 
increase in Tn-C deposition in the RBM at 24h post-challenge (Phipps et al., 
2004b). With regard to this thesis, Thompson et al. reported induction of Tn-
C expression by bronchial epithelial cells following challenge with exogenous 
TGF-β2. Expression was also increased following a model “scrape” injury 
(Thompson et al., 2006). 
1.1.5.3 (Myo)fibroblasts 
Fibroblasts are the predominant cell type in the lamina propria, responsible 
for the majority of extracellular matrix production and of the lamina propria 
itself. 
The lamina propria appears ultrastructurally as loose connective tissue 
composed of collagens and proteoglycans, with longitudinal bundles of elastic 
fibres of elastin and fibrillin, and nerves. The major components of the 
extracellular matrix are described in Table 1.3. 
 
Component Function 
Fibrillar collagens (Types 
I, II, III, V) 
Resist tensile forces, mix with elastin to 
limit stretch and stop tearing of tissue. 
Hyaluronan 
–ve charge attracts +ve ions which draws 
water into matrix ∴ can withstand 
compressive forces 
Proteoglycans  
Withstands compressive forces. Bind FGF 
and other factors 
Tenascin 
Guides cell migration through integrin 
binding. 
Fibronectin 
Aids cell attachment to ECM, and cell 
migration through matrix 
Elastin Allow stretch of tissue.  
Laminin Cell adhesion at basal lamina 
Table 1.3 Extracellular matrix components of the bronchi.  
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Differentiation of fibroblasts to myofibroblasts occurs naturally during the 
tissue repair response, although persistence is associated with fibrosis 
(Brewster et al., 1990). Myofibroblasts gain a contractile function due to the 
accumulation of stress fibres and smooth muscle related proteins;  α-smooth 
muscle actin (α-SMA) is used as a marker of myofibroblast differentiation 
(Hinz et al., 2007a), and subepithelial collagen deposition in AWR is thought 
due to greater numbers of myofibroblasts in the lamina propria (Zhang et al., 
1994). Increased myofibroblast number correlates with RBM thickness 
(Gizycki et al., 1997) and differentiation follows TGF-β stimulation (Hu et al., 
2003). 
 
Asthmatic fibroblasts challenged with TGF-β2 upregulated smooth muscle 
related mRNA transcripts to a greater degree than healthy and were 
maximally primed at 10-fold lower concentration of TGF-β2 than healthy. This 
suggests that fibroblasts from asthmatic subjects may be more sensitive to 
TGF-β2 than healthy cells (Wicks et al., 2006). 
 
1.2 Transforming Growth Factor-β  
Transforming growth factor- β (TGF-β) is a pro-fibrogenic cytokine implicated 
in the remodelling and repair processes in the airways. TGF-β is part of the 
TGF-β superfamily of cytokines, of which there are around 40 mammalian 
members including bone morphogenetic proteins (BMP), activins and 
macrophage inhibitory cytokine-1 (MIC-1). TGF-β is considered a vital 
element in maintaining tissue homeostasis in the healthy lung, with effects on 
matrix production and turnover key to this process. Complex interlinking 
pathways of cell activation, proliferation, downregulation and mediator release 
are affected and regulated by active TGF-β, and disseminating the cytokine’s 
effects on individual cell types has provided data on the possible outcomes of 
activation in-vivo. Three isoforms of TGF-β have been identified in humans: 
TGF-β1, TGF-β2 and TGF-β3. Of these TGF-β1 is the best characterised. The 
individual isoforms are encoded on different genes. The majority of published 
data focuses on TGF-β1, however the role of TGF-β2 in asthmatic remodelling 
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and repair is gaining prominence and it is the TGF-β2 isoform that shall be 
evaluated in experimental work presented in this thesis.  
 
1.2.1  TGF-β  secretion 
TGF-β2 is first transcribed and translated as pre-pro-TGF-β, the pre section 
being an N-terminal 19 amino acid signal peptide for translocation to the 
Golgi, where the C-terminal pro-region is cleaved by a furin-like peptidase at a 
dibasic cleavage site (Figure 1.1). The cleaved pro-peptide forms the 75kDa 
homodimer of latency associated protein (LAP). The mature TGF-β is a 25kDa 
homodimer that non-covalently associates with LAP. The molecule is now 
designated latent TGF-β (LTGF-β) or the small latent complex (SLC). LAP 
covalently binds a latent TGF-β binding protein (LTBP) forming the large 
latent complex (LLC) (Figure 1.2) (Todorovic et al., 2005). LTBP is thought to 
anchor the TGF-β complex in the ECM by co-localising with fibrillins, thereby 
providing a reservoir of biologically inactive TGF-β (Chaudhry et al., 2007). 
The majority of this work was carried out on TGF-β1. 
 
The LTBPs are members of the LTBP-fibrillin superfamily as they have 
structural similarities with the fibrillins. The SLC of TGF-β2 can bind to either 
LTBP-1 or LTBP-3, both expressed in lung. Each isoform contains 4 cysteine 
rich (CR) domains. The third CR domain in each binds covalently to LAP. The 
cysteine rich domain at the N-terminus of the LTBP mediates covalent linking 
to the extracellular matrix. LTBPs may thus play a role in controlling 
bioavailability of TGF-β in tissues (Ramirez and Rifkin, 2009). 
 
1.2.2   TGF-β2 activation 
The SLC and LLC are biologically inactive complexes containing mature TGF-
β. Before receptor binding can occur TGF-β must disassociate from LAP. The 
activation of TGF-β can occur through several mechanisms. TGF-β2 LAP does 
not contain an argine-glycine-aspartic acid (RGD) sequence, and so does not 
appear to bind integrins as a method of activation as TGF-β1 and TGF-β3 do.  
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TGF-β latency is governed by LAP, as it blocks sites of receptor binding on the 
mature TGF-β dimer. Immobilisation on the cell surface may be required for 
presentation to proteases. This can occur via binding of mannose-6-phosphate 
(M-6-P) moieties of the LAP to M-6-P receptors (M-6-PR) on the cell surface 
(Yang et al., 2001). In this way plasminogen-derived plasmin has been shown 
to cleave LAP and activate TGF-β1 (Khalil et al., 1996). 
 
Activation of TGF-β1 and TGF-β2 has been demonstrated in various in-vitro 
systems through the activity of both serine and cysteine proteases. An 
overview of these studies is given in Table 1.4. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic of pre-pro-TGF-β2. The pre-TGF-β signal peptide targets 
the complex to the Golgi, where the pro-region is cleaved by a furin-like peptidase. 
TGF-β2 forms a mature, 25kDa homodimer, which non-covalently associates with a 
homodimer of the pro-region, now termed latency-associated peptide (LAP). 
 
 
 
 
 
 
 
 
 
Pre- Pro- TGF-β2 
414 aa 
RXX
R 112 aa 283 aa 19 aa 
Furin cleavage site 
 Gaynor A. Campbell 
  30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Schematic of mature TGF-β2 in the large latent complex (LLC) 
25kDa mature TGF-β2 associated with 75kDa LAP forms the small latent complex 
(SLC). LAP has covalently bound a latent TGF-β binding protein (LTBP-1S), forming 
the large latent complex (LLC).  
 
 
 
 
 
 
Mature TGF-β2 
Latency associated peptide (LAP) 
LTBP-1S 
8-cys repeat 
Hybrid domain 
Ca2+ binding EGF-like repeat 
Non-Ca2+ binding EGF-like repeat 
Hinge region 
 
Key 
 Protease Class 
TGF-β  
isoform 
Cell 
associated? 
Reference 
Plasmin Serine TGF-β1 Cell assoc. 
(Khalil et al., 
1996; Lyons et 
al., 1988) 
Prostate-specific 
antigen (PSA) 
Serine TGF-β2 
Cell-free & 
assoc. 
(Dallas et al., 
2004) 
Tryptase Serine TGF-β1 
Cell-free & 
assoc. 
(Tatler et al., 
2008) 
Der f 1 Cysteine TGF-β1 Cell-free 
(Nakamura et 
al., 2009) 
Calpain Cysteine TGF-β1 
Cell-free & 
assoc. 
(Abe et al., 
1998) 
Cathepsin B Cysteine TGF-β1 Cell-assoc. 
(Gantt et al., 
2003) 
Cathepsin B/D Cysteine TGF-β1 
Cell-free & 
assoc. 
(Oursler et al., 
1993) 
Table 1.4 Proteinases shown to activate latent TGF-β  isoforms 
 
1.2.3   TGF-β  Receptors 
There are three subsets of  transmembrane TGF-β receptors, Type I (TβR-I) 
and Type II (TβR-II), both of which are required for TGF-β signal transduction 
and TβRIII. The TβR-I family contains two receptors which bind TGF-β: 
activin receptor-like kinase 1 (ALK-1) and ALK-5. TβR-I have intrinsic 
serine/threonine kinase activity in the cytoplasmic portion and a short 
cysteine-rich extracellular domain, features which are shared by TβR-II. TβR-
II differ from TβR-I in a longer cytoplasmic domain and a spacer region lying 
between transmembrane and kinase sequences. TβR-II lack the characteristic 
glycine/serine rich domain found next to the kinase domain in TβR-I.  
 
TGF-β2 must bind the 250-350 kDa proteoglycan betaglycan, also known as 
TGF-β receptor type III (TβR-III), to mediate strong binding to TβR-II, 
although recent evidence shows a splice variant of TβR-II can bind TGF-β2 
without the requirement for betaglycan (del Re et al., 2004a). Once a TβR-II 
dimer is bound by active TGF-β, the dimeric TβR-I associates forming a 
tetrameric receptor complex. The cytoplasmic domain of TβR-I is 
phosphorylated by TβR-II, signalling the start of the signal transduction 
pathway.  
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1.2.4   TGF-β-Smad signalling  
The primary signalling pathway of TGF-β is Smad-dependent. Smads are a 
family of eight intracellular transcription factors classified as receptor 
associated (R-Smad 1, 2, 3, 5 and 8), common (Co-Smad 4) or inhibitory (I-
Smad 6 and 7). R-Smads 2 and 3 are activated by TGF-β (and activin) binding. 
The Smad proteins consist of two globular domains designated Mad-homology 
1 (MH1) and MH2 joined by a flexible linker. In the inactive form, the MH1 
and MH2 domains are bound together (Massagué et al., 2005). 
 
Upon ALK-5 phosphorylation R-Smad 2 and R-Smad 3 are presented to the 
receptor complex by the membrane-anchored Smad anchor for receptor 
activation (SARA) which binds a Smad interaction motif (SIM) in the linker 
region. R-Smad2 and 3 are phosphorylated by ALK-5 which leads to 
dissociation from SARA, the MH1 and MH2 domains are forced apart by the 
conformational change then dimerisation in the cell cytoplasm. The R-Smad2 
and 3 heterodimers associate with Co-Smad4 which aids translocation into the 
nucleus.  In the nucleus the complex binds to Smad-binding elements (SBE), 
specific motifs found in the promoter regions of genes regulated by TGF-β.  
 
R-Smad activation is regulated by kinase activity in the cell cytoplasm. 
Phosphorylation of residues in the linker regions of R-Smads by MAPKs 
(mitogen associated protein kinases) such as Erk MAPK in the cytoplasm 
blocks Smad translocation into the nucleus and therefore abrogates TGF-β 
signalling.  
 
Nuclear Smad complexes can co-operate with transcription factors and DNA 
binding proteins to influence gene transcription. Co-Smad4 is important in 
these interactions stabilises the association of R-Smads with DNA binding 
factors.  Co-factor identity is dependent upon cell type and environment, thus 
TGF-β isoforms have multiple and wide ranging effects on many cell types. A 
selection of known Smad2 and Smad3 co-factors are shown in Table 1.5. 
 Smad Co-
factor 
Interacting 
Smad 
Results of interaction 
Max Smad3 Inhibition of Smad3-mediated transcription 
TFE3 Smad3 
Synergistic cooperative effects on PAI-1 and 
Smad7 genes. 
c-Fos Smad3 Associate at AP-1-dependent target genes 
c-Jun, JunB, 
JunD 
Smad3 
+ve and –ve regulation of Smad3 activity 
FoxH1 Smad2 & 3 Bind Activin-responsive promoters 
FoxO Smad2 & 3 Regulation of p21 expression 
Estrogen 
receptor 
Smad3 
Repression of Smad3 target genes 
Glucocorticoid 
receptor 
Smad3 
Inhibition of Smad3 activity 
Sp1 Smad2 
Activation of numerous target genes eg. P15, 
PAI-1, Smad7 and collagen.  
IRF-7 Smad3 Activation of IRF-7 transactivation effects 
NFκB p52 Smad3 Activation of κB site 
P53 Smad2 Synergism and antagonism of Smad2 targets 
Table 1.5 Smad2 and Smad3 binding partners and their major function. 
Adapted from (Feng and Derynck, 2005; Van Eerdewegh et al., 2002). 
 
TGF-β1 has been shown to induce expression of cdk inhibitors p15, p21 and 
p27 in bronchial epithelial cells, and p21 is increased in asthmatic epithelium 
(Puddicombe et al., 2003).  In the case of p21 this occurs when Smad3 
interacts with the forkhead protein FoxO and binds to the p21 gene promoter 
region. In the zinc-finger protein family Sp1 interacts with Smad2, 3 and 4. 
Association with Smad2 and Smad3 can result in transcription of α2(I) 
collagen, Smad7 and PAI-1 genes, all of which may have further downstream 
effects on AWR. Smad3 cooperation with the co-factor TFE3 also leads to 
transcription of PAI-1 and Smad7, and also the laminin-γ-chain gene (Feng 
and Derynck, 2005). TGF-β mediated upregulation of these matrix-associated 
genes could contribute to AWR.   
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1.2.5   TGF-β  in asthma 
The predominance of TGF-β2 in the epithelial layer and immediately below in 
healthy and asthmatic bronchial tissue suggests it may be of interest in AWR. 
Much of the literature investigating TGF-β in the airway refers  to the TGF-β1 
isoform. 
 
Bronchial biopsy studies provide a snapshot of bronchial tissue in time. 
Thirteen atopic asthmatics were biopsied before and 24h following allergen 
challenge (HDM, cat dander or grass pollen, dependent on most reactive skin 
prick test reponse), and TGF-β1, TGF-β2 and TGF-β3  stained  for. All three 
isoforms were present in the epithelium in this study, however only TGF-β2 
showed a significant increase in expression following allergen challenge. 
Tenascin-C expression was also increased post-challenge (Torrego et al., 
2007). These results are of relevance to this study, however it must be noted 
that no healthy controls were included.  
 
Batra et al. undertook a timecourse study of BAL cytokine levels, with 
timepoint 0 compared to 24h, 1 week and 2 weeks following allergen challenge 
(ragweed extract) in both healthy controls and mild asthmatics. TGF-β2 was 
greater at baseline in healthy controls compared with asthmatics in this study. 
Following allergen challenge, TGF-β1, TGF-β2, IL-4 and IL-13 were increased 
in asthmatic samples only, and IL-4 remained elevated the longest. This 
clearly indicates a role for TGF-β2 in healthy lung, that is dysregulated in 
asthmatics (Batra et al., 2004). 
 
Following on from Batra and colleagues BAL analysis, Balzar et al. reported on 
a biopsy-based study of severe asthmatics compared with mild asthmatics and 
healthy controls. All tissue was at baseline, that is no allergen challenge took 
place. Following assessment of all 3 TGF-β isoforms in biopsy tissue, the 
authors reported only the TGF-β2 isoform was upregulated in asthmatics. It 
was also reported that CTGF (a downstream marker of TGF-β activation) was 
downregulated in all asthmatics. This could be attributable to the decreased 
TβRI and low levels of TβRIII descibed in the asthmatic tissue (Balzar et al., 
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2005a). It is possible that this downregulation of receptor expression is due to 
maintenance of lung homeostasis. If there are consistently high levels of active 
TGF-β2, then sensitivity to the cytokine may become blunted.  
 
Healthy control and mild asthmatic bronchial biopsy tissue was analysed for 
expression of TGF-β1 and TGF-β2 at baseline by Chu and colleagues, who 
demonstrated increased TGF-β2 over TGF-β1 in both sample cohorts. 
Furthermore, TGF-β2 was significantly increased in asthmatic compared with 
healthy tissue. The authors also established primary bronchial epithelial cell 
cultures at air-liquid interface (ALI) from a subset of study participants, and 
assessed mucin production as a marker of goblet cell  hyperplasia following 
TGF-β exposure. TGF-β2 exposure led to a non-significant increase in mucin 
protein secretion, however no changes were observed following TGF-β1 
exposure (Chu et al., 2004). 
 
The results discussed above strongly indicate a role for epithelial-derived TGF-
β2 in AWR. Reactivation of the epithelial-mesenchymal trophic unit (EMTU) 
of epithelium and underlying mesenchymal cells (fibroblasts) may  drive AWR 
in asthma (Holgate et al., 2004; Knight et al., 2004). Several groups have 
published in-vitro studies purporting to mimic this reactivation through 
challenge of the epithelium.  
 
Thompson et al. determined levels of TGF-β2 from healthy HBECs at baseline 
and following scrape injury. TGF-β1 was below the level of detection in 
conditioned medium (CM), however active TGF-β2 rose from 50-70pg/ml to 
around 150pg/ml following injury; tenascin C was also increased. Exogenous 
TGF-β2 alone induced Tn-C expression also (Thompson et al., 2006). This is 
of interest as tenascin C has been suggested as a marker of EMTU reactivation. 
Exposure of lung fibroblasts either to scrape-injured epithelial CM or in co-
culture below the injured cells led to significant increases in α-SMA protein 
expression, indicative of myofibroblast differentiation. Only healthy cells were 
used in this study, so again the role of TGF-β2 in maintaining lung 
homeostasis upon injury is shown.  
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Tschumperlin et al. devised a mechanical stress model for HBEC culture at 
ALI, to mimic the bronchoconstriction aspect of the asthmatic response. 
Increased active TGF-β2 secretion was reported, but mRNA levels remained 
steady, suggesting the epithelial cells contained a pre-formed pool of TGF-β2, 
and protein was not newly synthesised. CM also resulted in increased collagen 
synthesis measured by [3H]proline incorporation (Tschumperlin, 2003).  
 
Continuous exposure of HBEC cultures to IL-13 led to a “pro-fibrotic” cell 
phenotype. HBEC cultures in this study continously secreted higher levels of 
active TGF-β2 than controls, and exposure of fibroblasts to IL-13 pre-treated 
cultures led to increases in collagen production. The authors suggest that the 
continuous exposure to the Th2 cytokine IL-13 models the allergic asthmatic 
airway (Malavia et al., 2008).  
 
It is apparent from these studies that environmental insult, including physical 
injury/stress and exogenous TGF-β2 in culture,  of epithelia leads to 
alterations in cell behaviour that drive remodelling in underlying fibroblasts. 
Allergen challenge of human subjects and subsequent alterations in TGF-β2 
levels demostrated a novel mechanism by which AWR responses could be 
continuously driven.  
1.3   The role of house dust mite allergens in asthma  
An allergen is an antigen capable of provoking an IgE antibody response. The 
biological function of an allergen has the potential to affect the physiological 
response. In allergen nomenclature, the first three letters of the Linnean genus 
are used, together with a single letter of species name and a number denoting 
the order in which allergens were purified. Hence, the first purified allergen of 
house dust mite (HDM) Dermatophagoides pteronyssinus becomes Der p 1. 
Dermatophagoides pterronysinus is a common source of allergens and 
subsequent allergic sensitisation in Western Europe. The pathogenesis of 
allergic asthma may in part be due to the proteolytic activity of HDM allergens 
including Der p 1 (Asokananthan et al., 2002; Gough et al., 1999; Wan et al., 
1999) 
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Inflammatory responses to HDM allergens are well documented (Custovic et 
al., 1996). In-vitro challenges of healthy control and asthmatic epithelial cells 
consistently show release of proinflammatory cytokines such as GM-CSF, IL-6 
and IL-8 following challenge that is further upregulated in asthma (Lordan et 
al., 2002; Pichavant et al., 2005; Rusznak et al., 2001). Activity of a selection 
of HDM allergens is given in Table 1.6. 
 
Allergen 
Biochemical 
Function 
Effect of cell 
challenge 
Reference 
Der p 1 Cysteine protease 
Inactivated elastase 
inhibitors 
Enhanced DC 
recruitment 
Cleaved CD25 
(Brown et al., 
2003; Pichavant et 
al., 2005) 
(Gough et al., 
1999) 
Der p 2 
Unknown, no 
protease activity 
GM-CSF, IL-6 & 
IL-8 release by 
epithelial cells 
(Osterlund et al., 
2009) 
Der p 3 
 
Serine protease 
(trypsin) 
Cleavage of 
complement C3 & 
C5. 
PAR-2 activation 
(Maruo et al., 1997; 
Sun et al., 2001) 
Der p 5 
 
Unknown, no 
protease activity 
IL-6 & IL-8 release 
by epithelial cells 
(Kauffman et al., 
2006) 
Der p 9 
Collagenolytic 
serine protease 
PAR-2 activation (Sun et al., 2001) 
Table 1.6 HDM-derived major allergens and selected effects 
 
As seen in Table 1.6, both proteolytically inert and active allergens activate the 
respiratory epithelium to varying degrees. Also of importance in asthma 
pathogenesis is the ability of HDM allergens to disrupt the integrity of the 
epithelial layer. Wan et al. illustrated tight junction breakdown and increase in 
epithelial permeability in 16HBE14o- cultures challenged with Der p 1 (Wan et 
al., 2000). The loss of airway epithelial integrity may be key to downstream 
effects of HDM exposure, however this was not investigated in this study. 
The proteolytic activity of HDM allergens is of interest in this study.  Exposure 
of BEAS-2B cells to Der p 1 or Der p 9 revealed that at concentrations required 
for cytokine (GM-CSF, IL-6, IL-8) release (10µg/ml) IL-6 was proteolytically 
degraded by both Der p 1 and Der p 9 (King et al., 1998). Cytokine secretion 
responses are partly mediated by PAR-2 cleavage (Adam et al., 2006). PAR-2 
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is upregulated in asthmatic epithelium (Knight et al., 2001), and in-vitro Der 
p 1 challenge of primary HBECs  showed increased secretion of GM-CSF, IL-6 
and IL-8 by allergic asthmatic HBECs over non-atopic controls (Pichavant et 
al., 2005).  
 
The reports above all used single purified allergens of Der p. Heterogenous 
mixtures of proteolytically active HDM extracts may exert additonal effects. 
HDM extracts are variable preparations between companies/lab groups, as 
they are highly dependent upon the source material and the method of 
preparation. For example, an aqueous extract prepared from frozen whole 
mites will contain substantially  less Der p 1 than a preparation that contains a 
variable mix of whole mites, nymphs (the larval stage), fecal pellets, eggs and 
spent culture media (Jeong et al., 2010; Thomas et al., 2002). Der p 1 and Der 
p 2 are thought to have a role in the mite gut, and are concentrated in fecal 
pellets (Park et al., 2000). Variation in cellular responses between groups may 
be due to different formulations of the extracts used, and this should be borne 
in mind when assessing results.  
 
Repeated insult to the lung through allergic responses, with the resultant 
activation of cell types including epithelial cells, fibroblasts, mast cells and 
eosinophils may promote the airway wall remodelling seen in asthmatic lung, 
namely increased deposition of collagens and other proteins in the basement 
membrane and mucosa, myofibroblast differentiation, goblet cell hypertrophy 
and submucosal gland hyperplasia, and smooth muscle hyperplasia. Holgate 
et al. propose the reactivation of a developmental unit, the epithelial-
mesenchymal trophic unit (EMTU), as the source of remodelling phenomena,  
1.4.   Aims and hypothesis 
Decreased lung function in asthma has been partially attributed to airway wall 
remodelling. Increases in the pro-fibrogenic cytokine TGF-β2 have been 
reported in asthmatic tissue and BAL fluid. It is therefore hypothesised here 
that alterations in active TGF-β2 levels contribute to airway wall remodelling 
in the asthmatic lung.    
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The aims of this project are: 
1. To identify and measure AWR markers in healthy and asthmatic human 
bronchial biopsy tissue, including reticular basement membrane 
thickening, myofibroblast differentiation and TGF-β2 expression 
2. To identify whether house dust mite extracts can activate latent TGF-β2 
secreted by bronchial epithelial cells. 
3. To assess whether asthmatic bronchial fibroblasts are intrinsically more 
sensitive to the pro-remodelling effects of TGF-β2 than healthy 
fibroblasts. 
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Chapter 2: Materials and Methods 
 
Materials were obtained from Invitrogen (Paisley, UK), unless otherwise 
stated.  
2.1   Tissue Culture 
Human bronchial epithelial and fibroblast cells were required for this project 
and were obtained from commercial and non-commercial sources. An SV-40 
transformed bronchial epithelial cell line was also used: 16HBE14o-. Tissue 
culture procedures were carried out in a class II microbiological safety cabinet. 
 
2.1.1  Primary bronchial fibroblast isolation and 
maintenance  
Informed consent was obtained from healthy and asthmatic individuals 
attending Wythenshawe Hospital to undergo a single bronchoscopic 
procedure performed by a respiratory physician in the bronchoscopy suite of 
the North West Lung Centre. Information regarding patient smoking history, 
chest related medication, forced expiratory volume in 1 second (FEV1) and 
allergy was compiled. Ethical approval was given by South Manchester Ethics 
Committee.  
 
Bronchial biopsies were taken using 1.8mm alligator cup biopsy forceps (Type 
100503, Conmed UK Ltd, Swindon, UK) and dropped into sterile HBSS in the 
bronchoscopy suite. In the lab, biopsies were rinsed in chilled DMEM 
containing 100units/ml penicillin, 100ng/ml streptomycin and 25ng/ml 
amphotericin B before being placed in a 25cm2 tissue culture flask and allowed 
to attach for 30mins at 37°C, then 2ml of complete DMEM (containing 10% 
fetal calf serum (PAA Laboratories, Somerset, UK), 50 units/ml penicillin, 
50ng/ml streptomycin and 2mM L-glutamine) with 0.25ng/ml amphotericin 
B, was added dropwise. Medium was changed after 24 hours, and every 3 days 
following. Fibroblast-like (spindle-shaped) cell migration from biopsy tissue 
was seen around 14 days after seeding. Cultures were maintained until areas of 
80% confluence were seen, then cells passaged as follows. Medium was 
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removed and cells washed twice with PBS. 0.05% Trypsin/EDTA was added at 
1ml/flask and incubated at 37°C until cells detached. Active trypsin was 
diluted out by addition of 10ml complete DMEM. The cell suspension was 
centrifuged at 300g for 5 min, the cell pellet resuspended in complete DMEM 
and subcultured in a 75cm2 flask (Corning Life Sciences). Cells were expanded 
and subcultured at a 1:4 split, before being frozen at a low passage in DMEM 
freezing mix (80% complete DMEM, 10% FCS, 10% DMSO). Fibroblasts were 
used at passages 4 through 8. Donor characteristics are given in Table 2.1. 
Donor  Age Sex/Race 
FEV1 (% 
predicted) 
Steroid 
naïve? 
Smoking 
status 
Medication 
Asthmatic 
1 
22 M/Caucasian 96% Yes 
Non-
smoking 
Inhaled β2 
agonists  
Asthmatic 
2 
37 M/Caucasian 103% Yes 
Non-
smoking 
Inhaled β2 
agonists  
Healthy 2 23 F/Caucasian 108% Yes 
Non-
smoking 
None 
Table 2.1 Donor information for primary fibroblasts 
2.1.2  Maintenance of commercially sourced cells 
Commercially available primary cells from donors selected according to age, 
smoking history and health status were purchased from Lonza. One normal 
human lung fibroblast (NHLF) and three normal human bronchial epithelial 
cell (NHBEC) donors were used, and information provided by the company is 
shown in Table 2.2. 
Donor  Cell Type Sex/Race Age 
Smoking 
status 
4F0768 Fibroblast M/Caucasian 31 Non-smoking 
2F1578 Epithelial M/Caucasian 17 Non-smoking 
7F3081 Epithelial M/Caucasian 49 Non-smoking 
7F3000 Epithelial M/Hispanic 27 Non-smoking 
Table 2.2 Donor information obtained from supplier (Lonza). 
 
The SV-40 virally transformed airway epithelial cell line 16HBE14o- was 
obtained from within the University of Manchester (D. Thornton, Faculty of 
Life Sciences). These cells have epithelial features including tight junction 
formation and cytokeratin expression, but do not differentiate at ALI.  
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2.1.2.1  NHBEC maintenance  
Cryopreserved NHBEC were initially seeded at 3500 cells/cm2, as stipulated in 
Lonza literature, in Bronchial Epithelial Growth Medium (BEGM). BEGM 
consists of Bronchial Epithelial Basal Medium (BEBM) supplemented with a 
BEBM SingleQuotTM kit (bovine pituitary extact, epidermal growth factor, 
epinephrine, gentamicin-amphotericin, hydrocortisone, insulin, retinoic acid, 
triiodothyronine and transferrin).  Medium was changed every 2nd day. When 
80% confluent, cells were trypsinised and frozen down. Aliquots of 1 x 106 
NHBEC were expanded in 75 cm2 tissue culture flasks before experimental 
use. NHBEC were not used beyond passage 3 as the ability to differentiate at 
ALI is decreased in further passages.  
  
2.1.2.2  NHLF maintenance 
Initial seeding of cryopreserved cells (a single vial of 565,000 cells) used 
Fibroblast Basal Medium (FBM), a serum-free formulation supplemented with 
insulin and recombinant human fibroblast growth factor-B (rhFGF-B), as 
recommended by Lonza. The supplier’s protocol was followed, with cells 
seeded at 2500 cells/cm2. Subsequent expansion of NHLF used complete 
DMEM. Cells were used between passages 4 and 8. 
 
2.1.2.3  Transformed epithelial cell line maintenance 
Transformed epithelial cell line 16HBE14o- was grown in 75cm2 tissue culture 
flasks (Corning) containing 10ml minimum essential medium with Earle’s 
salts (Sigma-Aldrich), supplemented with 10% fetal calf serum (FCS), 
50units/ml penicillin, 50ng/ml streptomycin and 2mM L-glutamine. Medium 
was changed every 2-3 days. At 70-80% confluence, cells were passaged as for 
fibroblasts, subcultured at a 1:6 split. Cell stocks were routinely frozen in 
MEM freezing mix (80% complete MEM, 10% FCS, 10% DMSO).   
 
2.1.3   Air-liquid interface epithelial cell culture 
NHBEC are induced to differentiate into ciliated, goblet and basal cells when 
cultured at an air-liquid interface (ALI) in the presence of retinoic acid. For 
 Gaynor A. Campbell 
  43 
ALI culture, hanging inserts (Millipore, UK) were placed in 12-well culture 
plates, 1ml bronchial epithelial differentiation medium (BEDM: 50% serum-
free DMEM + 50% BEGM without triiodothyronine) added basolaterally and 
250µl apically to wet the polycarbonate membrane. The prepared inserts were 
equilibrated at 37°C for 30 min. 82500 BEC were seeded into each insert in 
250µl BEDM, to total 500µl BEDM apically. On day 1 media was changed 
apically and basolaterally, and every 2-3 days thereafter until cells reached 
around 80% confluence at day 7 after seeding. Cultures were brought to ALI 
by removing all medium, and replacing basolateral medium only with 1 ml 
BEDM Differentiation markers (mucus-production, cilia formation) were 
observed from day 7 onward. ALI cultures were maintained for up to 21 days.  
 
2.1.4  Bronchial epithelial cell challenge assays  
Primary HBEC challenges were carried out on cultures maintained at ALI for a 
minimum of 7 days to allow cell differentiation. Scratch assays were based on 
the protocol of Thompson et al. (Thompson et al., 2006). Briefly, a 200µl 
pipette tip was used to make a single score down the centre of the insert 
membrane, disrupting the epithelial cell layer. Cells were monitored 
microscopically, and conditioned medium taken from the basal compartment 
at specified timepoints. For mRNA analysis, culture membranes were cut from 
inserts and immersed in 1ml TRIzol reagent, cells lysed by repeated gentle 
pipetting, and frozen at -80°C until further processing (Section 2.5.1). 
 
To mimic environmental stresses, house dust mite preparations were applied 
to the apical surface, dissolved in serum-free DMEM. Control wells were 
exposed to SF-DMEM only. Cells were monitored and samples taken as for 
scratch assay cultures. LPS (Sigma-Aldrich) was added to basal media. 
 
Epithelial cell line (16HBE14o-) experiments were carried out under 
submerged culture conditions in 6 well culture plates at 80% confluence. 
Scratch assays were carried out as for primary BEC, using a 200µl pipette tip 
to make two scratches in a cross and immediately changing the medium, to 
 Gaynor A. Campbell 
  44 
remove apoptotic scratched cells that may produce a confounding effect on 
results. 
 
2.1.5  Bronchial fibroblast challenge studies 
Fibroblasts were seeded in 6 well tissue culture plates (Corning Life Sciences) 
and grown to 80% confluence in complete DMEM. Cells were quiesced for 24 
hours in serum-free DMEM prior to experimental procedures. 
 
For primary BEC conditioned media challenge studies, conditioned media was 
collected and pooled from individual donors from days 7-21 ALI, when apical-
basal polarity and differentiation were established. Scratch-injured BEC 
culture medium and HDM-exposed BEC culture medium were applied to 
fibroblast cultures and cells harvested at specified timepoints. TGF-β2 
stimulated fibroblast cultures were harvested in the same manner.  
 
Q-proteome mammalian protein kit was used (Qiagen, Crawley, UK) for whole 
cell lysate preparation, and the manufacturer’s protocol followed to produce 
samples stored at -20°C until further use.   
 
Collagen protein production was assessed in both culture supernatant and the 
cell layer using the Sircol collagen assay. For cell-associated collagen, 500µl 
0.5M acetic acid containing 1mM EDTA was pipetted onto cells, scraped into a 
1.5ml eppendorf and frozen at -20°C until use. Conditioned media for the 
assessment of soluble secreted collagen was collected and stored at -20°C until 
assayed.  
 
For mRNA extraction, cultures were washed briefly with PBS prior to the 
addition of TRIzol reagent at 1ml/well (see Section 2.5.1). 
 
2.1.6  Rat tail tendon collagen extraction 
Type I collagen was isolated from rat tail tendons as previously described 
(Piez, 1967). In a laminar flow hood ten frozen rat tails were thawed in 70% 
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IMS and the skin and tendon sheath removed to expose tendon fibres. Fibres 
were removed and submerged in 500ml sterile 0.5M acetic acid. The mixture 
was stirred for 48 hours at 4°C, then centrifuged at 1600g for 3 hours. The 
precipitate was discarded, and supernatant added to an equal volume of sterile 
1.5M NaCl. This was precipitated at 4°C for 48 hours, then centrifuged at 
1700g O/N. Supernatant was discarded and the pellets (now composed 
primarily of Type I collagen) were redissolved in 500ml sterile 0.5M acetic 
acid. The acidic collagen solution was dialysed against sterile water 3 times at 
4°C using 10000 MWCO dialysis tubing (Perbio Science, Crawlington, UK) for 
a total of 48 hours. The resultant Type I collagen solution was decanted into a 
sterile Duran bottle and stored at 4°C. Soluble collagen concentration was 
obtained using the Sircol assay kit (Biocolor Ltd., Ireland), following the 
manufacturer’s protocol. Rat tail derived collagen concentration was read from 
the standard curve prepared. 
 
2.2  Histological methods 
2.2.1  Bronchial biopsy tissue donor characteristics 
The characteristics of biopsy tissue donors used in Chapter 3 are shown in 
Table 2.3. All donors were caucasian, steroid naïve and reported no 
respiratory illness in 3 months prior to sampling. 
Group 
Sex Ratio 
M:F 
Age range 
(years) 
FEV1 % 
predicted 
range 
Current 
medication 
Asthmatic 9:3 19 - 58 85% - 115% 
β2-agonists 
only 
Healthy 5:5 22 - 47 94% - 117% None 
Table 2.3 Bronchial biopsy tissue donor demographics  
2.2.2   Tissue processing for histological analysis  
Biopsy samples were fixed O/N at 4°C in formal buffered saline (10%, pH 7.4), 
and stored in 50% industrial methylated spirits (IMS) prior to tissue 
processing. Samples were processed in a Tissue-Tek Vacuum Infiltration 
Processor (Bayer Diagnostics, Newbury, UK) running a dehydration and wax 
infiltration program as detailed in Table 2.2. Samples were embedded in 
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paraffin wax blocks and allowed to set O/N. Wax blocks were trimmed and 
sectioned at 4-5µm on a Reichert-Jung 2030 microtome (C. Reichert AG, 
Wien, Austria) fitted with disposable Accu-edge blades (Sakura Finetek, 
Zoeterwoude, The Netherlands). Sections were floated on cold deionised water 
then transferred to a 40°C water bath to smooth “wrinkling” of the tissue 
samples. Sections were collected onto Poly-L-Lysine coated microscope slides 
(Menzel GmbH, Braunschweig, Germany) and dried on a 40°C heated block 
before storage at room temperature, protected from light.        
 Step Solution 
Time 
(min) 
Temperature 
(°C) 
1 50% IMS 45 Ambient 
2 70% IMS 45 Ambient 
3 90% IMS 60 35 
4 100% IMS 30 35 
5 100% IMS 30 35 
6 100% IMS 60 35 
7 Toluene 30 35 
8 Toluene 30 35 
9 Toluene 60 50 
10 1st Wax 30 60 
11 2nd Wax 30 60 
12 3rd Wax 30 60 
13 4th Wax 60 60 
 
Table 2.2 Tissue-Tek Vacuum infiltration processor program for wax 
embedding of biopsy tissue. In each step an ambient pressure/vacuum cycle 
ensured complete infiltration of the tissue. 
 
2.2.3  Histological staining techniques 
Tissue sections were dewaxed by immersion in two consecutive xylene baths, 
followed by rehydration through a series of graded alcohols (IMS) (100%, 
100%, 90%, 70% and 50%), and immersion in tap water. Haemotoxylin and 
eosin staining was used to demonstrate general tissue architecture, whilst 
Masson’s trichrome identified the collagen and Miller’s elastin stain the 
presence of elastic fibres throughout the tissue. Standard histological stains as 
listed in “Theory and Practice of Histological Techniques” (Bancroft and 
Stevens, 1990) were prepared and followed with the exception of periodic acid 
solution and Schiff’s reagent, which were purchased from Sigma-Aldrich 
(Poole, UK). For further details of staining techniques, see Appendix A.  
 
2.3  Immunohistochemistry  
Tissue sections were dewaxed and rehydrated as for histological staining. 
Briefly, endogenous peroxidase activity was quenched by incubation with 1% 
hydrogen peroxide solution in methanol. Serum from the animal in which the 
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secondary antibody was raised was used to block sites of non specific binding, 
before samples were incubated with primary antibody in BSA-containing 
antibody diluent. After washing, incubation with biotin-conjugated secondary 
antibody followed, or antibody diluent without antibody as negative control, 
for 1 hour. Primary antibodies used are shown in Table 2.4. After further 
washing, 30 minutes of avidin-biotin conjugation using a Vectastain Elite 
Standard ABC kit (Vector Labs Ltd., Peterborough, UK) was carried out at RT. 
Slides were washed, rinsed in distilled water and diaminobenzidine (DAB) 
(Vector Labs Ltd.) substrate incubated on sections for between 1 and 5 min. 
Slides were rinsed in distilled water and counterstained with Harris’s 
haematoxylin for 30 seconds before dehydration through a series of alcohols 
into xylene, and mounted using Depex mounting medium (BDH Lab Supplies, 
Poole, UK). 
 
Antigen Raised 
in 
Dilution 
used 
Protein 
concentration Supplier 
TGF-β1 Rabbit 1/400 200µg/ml Santa Cruz 
TGF-β2 Rabbit 1/400 200µg/ml Santa 
Cruz 
TβRIII Goat 1/200 200µg/ml Santa Cruz 
α-SMA Mouse 1/400 4.5mg/ml Sigma-
Aldrich 
Tenascin C Rabbit 1/500 100µg/ml Monosan 
Occludin Goat 1/400 200µg/ml Santa Cruz 
β-tubulin IV Mouse 1/400 500µg/ml Sigma-
Aldrich 
Anti-rabbit IgG, 
biotinylated 
Donkey 1/1000 500µg/ml Amersham 
Anti-goat IgG, 
biotinylated 
Rabbit 1/2000 500µg/ml Dako 
Anti-mouse IgG, 
biotinylated 
Goat 1/2000 0.5 mg/ml Dako 
Table 2.4 Primary and secondary antibodies used in biopsy assessments 
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2.4  Microscopy and Image analysis 
Standard histological stains (H&E, Masson’s trichrome, PAS-Alcian blue) were 
used to highlight tissue architecture. Stained sections were viewed using an 
Axiostar plus light microscope (Zeiss, Hertfordshire, UK), with 4x, 10x, 20x 
and 40x objective lenses. Images were captured using a Spot-32 digital camera 
(Diagnostic Instruments Inc, USA) coupled with Spot-RT version 2.1.2 
software running on a Dell Optiplex GX620 computer. Images of a 100µm 
graticule (Psyer, SKI Limited, UK) were taken at the same magnification for 
calibration purposes. 
 
All image analysis was performed using Image Pro-Plus software (Media 
Cybernetics, California, USA), using a graticule image to calibrate. Scoring was 
performed blinded, and repeat scoring/measurements were made at least 2 
weeks apart. 
 
2.4.1   Determination of basement membrane thickness 
For RBM measurements, either Masson’s trichrome or PAS-Alcian blue 
stained sections were analysed as both allow clear differentiation between the 
reticular basement membrane and underlying mucosa.  
 
Three sections with sufficient intact epithelium to confirm correct orientation 
of the reticular basement membrane were selected from throughout each 
biopsy. Images were taken at x200 magnification, and an outline was traced 
around the horizontal sections of reticular basement membrane on each 
section. The selections were filled and converted to objects (Figure 2.1). 
Objects were converted to white against a black background, and merged with 
an image of horizontal lines set at 2µm intervals. All bright object pixel heights 
created were calculated, and converted to microns. This produced a 
measurement at 2µm intervals along the selected RBM. A graticule image at 
x200 magnification was used to calibrate measurements. Each section was 
viewed and analysed on three separate occassions to give an average, and 
ensure intra-observer variation was within acceptable limits (below 10%). 
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Figure 2.1 Measurement of reticular basement membrane thickness.  
Images taken at an original magnification of 200x were orientated using the Image 
Pro-plus software package so maximal length of basement membrane was horizontal. 
A. Basement membrane sections were  selected. B. A grid mask was applied to convert 
selected areas to a set of objects.  Object heights were calculated, and the average 
taken.  
2.4.2  α-Smooth muscle actin immunoreactive cell counts 
To quantify levels of myofibroblast differentiation in healthy and asthmatic 
bronchial biopsy tissue, three 5µm sections of tissue from throughout each 
biopsy were immunostained for the presence of α-smooth muscle actin (α-
SMA) protein, a commonly used marker of muscle-like cells, with a 
monoclonal antibody raised in mouse. Smooth muscle bands within the tissue 
were used as a positive control, and normal mouse IgG as a negative control. 
Images of α-SMA immunostained tissue were taken at x20 magnification for 
assessment. Positive cells were counted to a depth of 100µm below a 1mm 
length of RBM, giving a total area analysed of 100µm2. Blood vessels and 
smooth muscle bundles were not included. The area examined was limited to 
this depth to assess cells directly involved in the EMTU. Results were 
expressed as a percentage of total cells identified. 
A
. 
B. 
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2.4.3  Immuno-quantitation of TGF-β2, Tenascin C and TβRIII 
A single section was selected from each biopsy. The standard 
immunohistochemistry protocol was followed, with the addition of a sodium 
citrate antigen retrieval step prior to endogenous peroxidase reduction. Slides 
were fully submerged in 10mM citrate buffer pH 6.0, heated on full power in a 
900watt microwave for 4min then allowed to cool for 20min before 
proceeding. For TGF-β2 stained sections, the epithelium, lamina propria and 
smooth muscle were scored seperately on a scale of 0-3: 0= no/background 
immunoreactivity, 1= low, 2= moderate and 3= intense immunoreactivity. In 
tenascin C stained sections the area to a depth of 100µm below the RBM, and 
including the epithelial layer, was assessed on scale of 0-3 as for TGF-β2. 
TβRIII stained sections were assessed for total staining as for tenascin C.  
 
2.5   Molecular Biology 
Analysis of messenger RNA levels of cells was carried out to determine 
changes in gene expression following exposure to TGF-β2, conditioned 
medium or other challenge. Although gene expression levels do not necessarily 
correlate to increased protein levels, analysis of mRNA identifies increases or 
decreases in gene transcription levels in response to stimulation.  All materials 
were molecular biology grade. 
 
2.5.1  RNA isolation 
Cultured cells in monolayer were washed twice in pre-warmed PBS, then 
TRIzol reagent added at 20µl/cm2 or 1ml/sample, whichever was the greater. 
Cells were scraped from the culture surface using a disposable cell scraper and 
transferred to a 1.5ml microtube. For membrane grown BEC, after washing the 
membrane was cut from the insert and placed into a 1.5ml eppendorf before 
adding TRIzol reagent. BEC were lysed by repeated gentle pipetting through a 
200µl tip. Samples were incubated at room temperature for 5 min to allow 
dissociation of nucleoprotein complexes. Following centrifugation at 12000g 
for 10 min at 4°C, the supernatant was transferred to a fresh microtube. 200µl 
chloroform per ml of TRIzol reagent was added and shaken vigorously for 15 
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sec before incubating at room temperature for 2-3min. Samples were then 
centrifuged at 12000g for 15 min at 4°C. The upper aqueous phase containing 
RNA was pipetted into a clean microtube, and the same volume of isopropyl 
alcohol added. Following incubation at -20°C for 1 hour, samples were 
centrifuged at 12000g for 10 min at 4°C. The resulting pellet was washed with 
1ml of 75% ethanol, mixed by brief vortexing and re-centrifuged at 7500g for 5 
min at 4°C. The pelleted sample was then air-dried before 30µl water was 
added and the sample incubated at 60°C in a water bath for 10 min. The 
purified nucleic acids were stored at -40°C, or -80°C for longer term storage. 
 
2.5.2  Determination of RNA Quantity and Quality 
A ND-1000 Nanodrop spectrophotometer (Lab-tech International, East 
Sussex, UK) coupled with ND-1000 version 3.5.2 software was used to 
determine RNA quantity and quality. A 1µl sample was used in this analysis. 
Measurement of absorbance at 260nm (A260) and at 280nm (A280) 
wavelength was taken, and the A260/A280 ratio determined. An A260/A280 
ratio of between 1.7 and 2.1 was accepted as being of sufficient quality for 
subsequent use.   
 
2.5.3  DNase removal of of contaminating genomic DNA 
A commercial DNase kit (Sigma Aldrich, UK) was used to eradicate DNA 
contamination. Thin-walled PCR tubes containing 1µg sample RNA in 8µl 
molecular grade water, 1µl 10x reaction buffer and 1µl DNase I (1Unit/µl) were 
incubated at RT for 15 min, then 1µl stop solution added, and tubes heated to 
70°C for 10 minutes to destroy residual DNase activity before chilling on ice.  
 
2.5.4  Reverse transcription of mRNA to cDNA 
1µl dNTP mix and 1µl random nonamers were added to the 1µg sample of 
DNase-treated mRNA, mixed and incubated at 65°C for 5 min. Microtubes 
were then placed on ice before adding: 4µl 5x First Strand buffer, 2µl DTT and 
1µl RNase OUT. Microtubes were incubated at 42°C for 2 min, 1µl Superscript 
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II Reverse Transcriptase added, and samples incubated at 25°C for 10 min, 
42°C for 50 min then the reaction stopped by heating to 70°C for 15 min. 
cDNA samples were stored at -20°C short-term, or at -80°C for longer term. 
 
2.5.5   Quantitative Real Time PCR 
cDNA samples were serially diluted 10-fold with molecular grade water. One 
sample was used to produce a standard curve by assigning arbitrary values of 
concentration to each dilution. SensiMixPlus SYBR 2x mastermix (Quantace, 
Finchley, UK) containing heat-activated DNA polymerase, dNTPs, 6mM 
MgCl2 and SYBR Green I dye, was used for all reactions. Primers were 
reconstituted in molecular grade water, and used in reactions at 15µM. For 
each 25µl reaction, 12.5µl mastermix, 0.225µl each of forward and reverse 
primers, 2.05µl water and 10µl cDNA was prepared. Reactions were pipetted 
into a 96 well plate (MJ Research, Hertfordshire, UK) in triplicate, alongside 
negative controls (water and non-transcribed RNA). Plates were sealed with 
Microseal ‘B’ sealer film (Bio-Rad, UK) and PCR performed on a MJ Research 
thermocycler  that monitored sample fluorescence. PCR cycling was as follows: 
 
1. Denaturation 10 min 95°C   
Followed by 40 cycles of:  
2.  Denaturation 15 sec 95°C 
3.  Annealing 1 min 60°c 
4.  Extension 30 sec 72°C (sample fluorescence read) 
 
Following cycle completion, a melt curve was performed to assess product 
specificity. The mixture is gradually heated and fluorescence measured. SYBR 
Green fluoresces when bound to double stranded DNA, so at the temperature 
the double stranded DNA is denatured, there is a sudden decrease in 
fluorescence. When this decrease is plotted as an inverse function of time, a 
single peak will show one specific product is formed.  
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All primer sets were designed using BLAST searches and Primer3 web-based 
software. Primer pairs resulted in one specific product as assessed by melt 
curve analyses.  
 
A threshold crossing the amplification curve in the linear phase was set to 
begin analysis of sample concentration. From the intercept of the threshold 
and the amplification curve the cycle threshold value was taken. This value 
was used to determine the arbitrary concentration of each standard sample. 
The concentrations of the standard were plotted against the cycle threshold to 
produce a standard curve. An R2 value of greater than 0.995 was required for 
the standard curve to be acceptable for determining concentrations of other 
samples in the reaction. When the arbitrary concentrations of interest were 
determined, all results from genes of interest were normalised against 
housekeeping genes, selected for stable expression as described in Section 
2.5.6. For fibroblast experiments the housekeeping genes used were GAPDH 
and ATP5B, and epithelial experiments used GAPDH. Results were analysed 
for statistical significance with Prism software package, using one-way 
ANOVA followed by Dunnett’s post-hoc with confidence intervals of 95%. 
 
2.5.6 Housekeeping gene selection for gene expression studies.  
Primer sets for ten candidate housekeeping genes were purchased from 
PrimerDesign Ltd, UK. and gene expression evaluated in control and 
experimentally modulated (TGF-β2 stimulated) NHLF cultures, following the 
protocol supplied. Results were analysed using the GeNorm software program 
(PrimerDesign Ltd) as previously described (Vandesompele et al., 2002). This 
identified the most stably expressed genes. Phospholipase A2 (YWH) and 
ubiquitin C (UBC) were least stable and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and Adenosine tri-phosphate synthase (ATP5B) 
were most stably expressed following TGF-β2 stimulation (Figure 2.2). 
Fibroblast q-PCR experimental results were therefore normalised to the 
geometric mean of GAPDH and ATP5B in all qPCR analyses. 
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Figure 2.2  Expression stability values of control genes. 
3 control and 3 TGF-β2 (1ng/ml) stimulated NHLF cultures were harvested at 24h, 
mRNA extracted and RT-PCR performed with 10 genes. GeNorm analysis of the 
results identified GAPDH and ATP5B as most stably expressed following TGF-β2 
exposure.  
 
2.5.7  Formaldehyde gel electrophoresis 
A 1.2% Formaldehyde agarose gel was prepared (Table 2.5) and cast. Once 
cool, the gel was equilibrated in 1x FA buffer for 30 min, before 1µg RNA 
samples in a total volume of 8µl were prepared in 2µl of 5x Loading buffer 
(Table 2.6), heated to 65°C for 5 min and chilled on ice before loading into gel. 
The gel was run at 100V for between 60-90 min and visualised with UV light. 
 1.2% FA Gel 10x FA Gel Buffer (pH 7.0) 
1.2g Agarose 200mM MOPS 
10ml 10x FA buffer 50mM Sodium acetate 
90ml RNase free water 10mM EDTA 
1.8ml 37% Formaldehyde For 1x buffer, 100ml 10x + 20ml 37% 
formaldehyde + 880ml RNase free water 
1ul 10mg/ml Ethidium bromide  
Table 2.5 Gel and gel buffer for nucleic acid quality assessment 
 
16µl saturated aqueous bromophenol blue 
80µl 500mM EDTA pH8 
720µl 37% Formaldehyde 
2ml 100% Glycerol 
3084µl Formamide 
4ml 10x FA gel buffer 
RNase free water to 10ml 
 
Table 2.6  5x RNA loading buffer  
 
2.6  Intra-cellular protein detection by immunoblot  
Fibroblasts were grown in 6 well plates in complete DMEM until 80% 
confluent. Wells were rinsed with serum-free DMEM and cells quiesced in SF-
DMEM for 24 hours prior to challenge. Cells were stimulated with a range of 
TGF-β2 concentrations (1ng-20ng/well), for 15 minutes at 37°C. Cells were 
washed with ice-cold PBS, 500µl ice-cold lysis buffer added, and cells scraped 
into a 1.5ml eppendorf. Cell lysates were mixed on a rotory mixer for 30 min at 
4°C, then centrifuged at 13000g for 5 min. The supernatant was retained and 
stored at -80°C until use in western blotting analyses.  
 
2.6.1   SDS-PAGE 
This technique allows the seperation of proteins according to molecular 
weight. 10% bis-tris acrylamide gel solutions were prepared and cast in 1mm 
BioRad glass plates.  20µg total protein samples in 2x Laemmli SDS-PAGE 
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sample buffer were loaded into wells. Electrophoresis was carried out at 200V 
for approximately 1hour. 
 
2.6.2   Western Blotting 
SDS-PAGE gels were transferred to a nitrocellulose membrane at 30V for 90 
min. After transfer, gels were discarded and the membrane probed with 
Ponceau stain (Sigma Aldrich) to confirm transfer of proteins onto the 
membrane. Non-specific protein binding was reduced by blocking the 
membrane in 5% non-fat milk powder in blotting buffer (10mM Tris-base, 
100mM NaCl, 0.1% Tween) for 1 hour at RT. Primary antibody diluted in 
blocking buffer was incubated on the membrane for 1 hour at RT or O/N at 
4°C, with constant agitation. The membrane was washed 6 times in blotting 
buffer before incubation with HRP-conjugated secondary antibody for 1 hour 
at RT. The membrane was washed as before then exposed to ECL reagent 
(Pierce) for 1 min. The membrane was drained, wrapped in clingfilm for 
protection and stored in a lightproof cassette until film exposure (within 30 
min of ECL reaction). In a darkroom, light sensitive film (Kodak) was placed 
against the membrane in the cassette and exposed for 1 min. The film was then 
removed and placed in developing solution until bands appeared, transferred 
to a fixative solution then rinsed in water before allowing to dry.  
 
2.8   Proteolytic activity assay 
The synthetic amino acid substrate, N-benzoyl-Phe-Val-Arg-p-nitroanilide 
hydrochloride (Sigma-Aldrich), was dissolved in methanol to a stock 
concentration of 25mM. All other components are listed in Table 2.7. 
 Component Diluent 
Final 
concentration 
Supplier 
Trypsin PBS 3U/ml Sigma-Aldrich 
Papain PBS 200mU/ml Sigma-Aldrich 
HDM Skin Prick Test 
Extract SF-DMEM 100000U/ml ALK-Abello 
HDM Fecal pellet prep. SF-DMEM 
1mg/ml 
(saturated) 
Indoor 
Biotechnologies 
E64 PBS 10µM Sigma-Aldrich 
PMSF Methanol 1mM Sigma-Aldrich 
Table 2.7 Proteolytic activity assay components 
 
50µl protease samples were added to a 96 well plate in triplicate. 10µl 
reducing agent (1mM DTT) was added to cysteine protease samples and 
allowed to equilibrate for 5min at RT. 20µl protease inhibitor, cysteine 
protease inhibitor E-64, serine inhibitor PMSF or Complete Mini protease 
inhibitor cocktail (Roche, UK) stock prepared as per the manufacturers 
instructions, was added to negative controls. All samples were made up to 
150µl with PBS and allowed to stand for 15min at RT. Amino acid substrate 
was diluted to a final concentration of 1mM, and 50µl added to each well. The 
plate was protected from light and held at 37°C. Absorbance readings at 
405nm were taken at 20min intervals over 2h and reaction progression curves 
prepared. 
 
2.9  TGF-β  detection by ELISA 
TGF-β1 and TGF-β2 Emax Immunoassay Systems were used according to 
manufacturer’s instructions (Promega UK Ltd, Southhampton, UK). These kits 
allow detection of biologically active TGF-β1 and TGF-β2 isoforms. 96-well 
Nunc Maxisorp ELISA plates (Thermo Fisher Scientific, UK) were coated with 
either a monoclonal TGF-β1 or -β2 specific capture antibody (supplied), O/N 
at 4°C in carbonate coating buffer. The plate was warmed to RT for 15 min and 
emptied, then 270µl of blocking buffer (supplied) pipetted into each well. The 
plate was sealed and incubated at 37°C for 35 min. Samples and standards 
were prepared. Active TGF-β standards are supplied at 1µg/ml, and were used 
between 15.6pg/ml and 1000pg/ml. The standard curve is linear between 
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32pg/ml and 1000pg/ml. Samples were either untreated to detect the active 
portion only or heated at 80°C for 6min (which activates any latent TGF-β 
present) to detect total (latent + active) TGF-β. Following activation samples 
were chilled on ice until use. Samples and standards (100µl/well) were 
incubated for 90 min on a plate shaker at RT. The plate was washed 5 times 
using TBS-Tween wash buffer then incubated with 100µl of rabbit anti-human 
TGF-β polyclonal antibody diluted 1:2000 in sample buffer (supplied), for 2 
hours at RT, on a plate shaker. Plates were washed 5 times as before, and an 
HRP-conjugated anti-rabbit antibody diluted 1:100 in sample buffer added at 
100µl well. A 2 hour incubation at RT with shaking followed. After plate 
washing, 100µl of room temperature TMB One solution was added to wells, 
and incubated at RT for 15 min. The chromogenic reaction was stopped with 
the addition of 100µl 1N HCl to each well. Absorbance was read at 450nm 
using an Asys UVM340 microplate reader (Biochrom Ltd., UK). A standard 
curve was created and sample concentration calculated.  
 
2.9   Data analysis and statistics 
All statistical analyses were carried out using Prism version 5.0b (GraphPad 
Software, USA). Values for immunohistochemistry measurement and scoring 
were analysed by Student’s unpaired t-test. Subsequent correlations were 
computed by Spearman’s rank correlation coefficient. Values for mRNA 
expression and protein production were analysed by one way ANOVA followed 
by Dunnett’s test where stimulated samples were compared to control only, or 
followed by Tukey’s test when all samples were compaired pair-wise. In all 
analyses a p value of <0.05 was considered significant.  
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Chapter 3: Evidence of airway wall remodelling in mild 
asthmatic bronchial biopsy tissue 
 
3.1   Overview 
Airway wall remodelling (AWR) contributes to the decline in respiratory 
function and symptom persistence observed in many asthmatics (Bai, 2009). 
AWR is independent of inflammation and largely unaffected by current 
medications  (Bourke et al., 2010; Ward and Walters, 2005). Thickening 
and/or stiffening of the conducting airway wall may reduce airflow by 
reduction of airway diameter (Aysola et al., 2008; James et al., 1989; Mitchell 
et al., 1998). 
 
Alterations in the composition of the asthmatic airway wall have been 
described, and include changes in both matrix and cellular components 
(Johnson and Burgess, 2004; Li and Wilson, 1997; Roche et al., 1989). 
Increased deposition of ECM molecules including collagens I, III and V in the 
lamina reticularis have been shown to lead to reticular basement membrane 
thickening (Wilson and Li, 1997), and have been linked to measures of airway 
hyper-responsiveness and asthma severity (Kariyawasam et al., 2007; 
Westergren-Thorsson et al., 2002). Differentiation of fibroblasts to a 
myofibroblastic phenotype can occur. Myofibroblasts are associated with 
fibrotic conditions and identified by accumulation of stress fibres and smooth 
muscle related proteins (Hinz et al., 2007b). Alterations in matrix production 
may follow this phenotypic change due to increased activation and matrix 
secretory properties of myofibroblasts. Additional structural changes observed 
in asthma include goblet cell hypertrophy, submucosal gland hyperplasia, 
smooth muscle hypertrophy and increased angiogenesis (Johnson and 
Burgess, 2004; Ordoñez et al., 2001). 
 
Reactivation of the epithelial-mesenchymal trophic unit has been suggested as 
an initiator of AWR in asthma (Holgate et al., 2004). Comprising the 
epithelium, lamina reticularis and cells immediately adjacent in the lamina 
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propria, the EMTU is identified during embryonic development by tenascin C 
deposition. Tenascin C is increased in asthmatic bronchial biopsy tissue 
following segmental allergen challenge and increased expression has been 
identified in asthmatic biopsy tissue (Flood-Page et al., 2003; Phipps et al., 
2004b). The EMTU represents the primary site of environment-host 
interaction in the lung, and continuous phenotypic or behavioural changes in 
cells residing in this area may be indicative of the breakdown of normal 
homeostasis.  
 
If the purported effects of AWR in the asthmatic individual arise from matrix 
component alterations and/or increases, it leads to the question:  what drives 
the remodelling response? As a pro-fibrotic cytokine, expressed in healthy 
lung and identified as an inducer of pathology in a number of fibrotic diseases, 
transforming growth factor-β has been investigated as a determinant of AWR 
in several studies. Correlations between TGF-β1 positive cell number and TGF-
β intra-cellular signalling with RBM thickness have been found (Sagara et al., 
2002; Vignola et al., 1997). It has been demonstrated that the TGF-β2 isoform 
predominates in bronchial tissue (Balzar et al., 2005a; Minshall et al., 1997; 
Torrego et al., 2007), and expression is increased upon epithelial cell injury 
(Holgate et al., 2000).For this reason, the TGF-β2 isoform was chosen for 
further investigation in this project.  
 
3.2  Aims and Hypothesis  
This chapter aims to address the hypothesis: there is no significant difference 
in AWR between healthy and asthmatic bronchial biopsy tissue. 
The hypothesis shall be tested through the following aims: 
 
1. Quantify remodelling phenomena: RBM thickness, myofibroblast 
differentiation and tenascin C deposition. 
2. Determine relative expression of TGF-β2 in healthy compared with 
asthmatic tissue.  
3. Assess correlation of TGF-β2 expression with remodelling phenomena. 
 
3.3  Results  
Bronchial biopsy tissue collected from 10 healthy and 12 mild asthmatic 
individuals was analysed. Paraffin wax embedded sections (5µm) were cut and 
collected onto poly-L-lysine coated slides. Standard histological stains were 
used to highlight tissue architecture and selected features. 
 
3.3.1  Reticular basement membrane thickness 
The RBM, or lamina reticularis, is composed primarily of collagens I, III and V 
and lies immediately below the true basement membrane- a thin meshwork of 
type IV collagen. RBM thickness has been has been used in several studies as a 
measure of AWR. In this study, periodic acid-Schiff’s /alcian blue or Masson’s 
trichrome stained sections were utilised, as both allowed a clear differentiation 
between the RBM and the underlying lamina propria.   
 
Three representative sections from each biopsy were analysed to produce an 
average measurement per sample. All 12 asthmatic and 10 healthy biopsy 
samples were examined and data normally distributed according to the 
Shapiro-Wilk test. Healthy tissue mean measurement range was 3.13-9.21µm 
(Figure 3.1), and 3.03-10.18µm in asthmatic tissue (Figure 3.2). Mean RBM 
thickness was significantly different between groups as calculated by unpaired 
t-test (Figure 3.3), with asthmatic tissue showing a significantly thickened 
RBM (healthy mean ± SEM = 6.038 ± 0.562; asthmatic mean ± SEM = 7.824 ± 
0.537; p<0.05). 
 
 
 
 
 
 
 
 
 Gaynor A. Campbell 
  63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Appearance of RBM in healthy bronchial biopsy tissue.  
Mean RBM thickness A=3.13µm and B= 9.21µm. PAS/Alcian blue stained 5µm 
sections of biopsy tissue were imaged using a Spot camera and analysed using Image 
Pro-plus. C- cilia; E- Epithelium; GC- Goblet cell; LP- Lamina Propria; R-RBM; S- 
Smooth muscle. Scalebar  - 100µm.  
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Figure 3.2 Appearance of RBM thickness in asthmatic bronchial biopsy 
tissue. Mean RBM thickness in A=5.28µm and B= 10.18µm. PAS/Alcian blue stained 
5µm sections of biopsy tissue were imaged using a Spot camera and analysed using 
Image Pro-plus. C- cilia; E- Epithelium; E(d)- Epithelium (denuded); GC- Goblet cell; 
LP- Lamina Propria; R-RBM; S- Smooth muscle. Scalebar  - 100µm. 
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Figure 3.3 Mean RBM thickness in healthy vs. asthmatic biopsy tissue.   
Asthmatic RBM was significantly thicker than healthy sample RBM. Each data point 
represents the average measurement in µm from 3 sections of one biopsy, one biopsy 
per subject. Healthy mean ± SEM = 6.038 ± 0.562, range 3.13-9.21; Asthmatic mean ± 
SEM= 7.824 ± 0.537, range 5.28-10.57; p<0.05 (n=10 healthy & n=12 asthmatic).  
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3.3.2   Myofibroblast frequency in lamina propria 
To assess myofibroblast differentiation, three sections from each biopsy were 
probed with a monoclonal anti-α-smooth muscle actin antibody. Bands of 
smooth muscle within the tissue were used as an internal positive control. α-
SMA positive cells in each section were counted, limited to a depth of 100µm 
beneath the true basement membrane as the interest here was on cells directly 
involved in epithelial-mesenchymal interactions. Sections where dehydration 
of the tissue had resulted in diffusely spread collagen fibres were excluded to 
ensure a similar area of complete lamina propria was assessed in each case. 
Smooth muscle, sub-mucosal gland and blood vessel-associated positive cells 
were not counted. Where cell type was in doubt, such as around small blood 
vessels, cell shape was accounted for, and cells of the characteristic spindle-
shape of fibroblasts were included. Data are expressed as the mean percentage 
of total cells stained positively (Figure 3.4). 
 
Myofibroblast frequency was significantly increased in asthmatic compared 
with healthy tissue (Figure 3.5), as assessed by unpaired t-test. 
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Figure 3.4 α-SMA immunoreactivity in healthy and asthmatic bronchial 
biopsy tissue. 5µm sections were probed with a monoclonal anti-α-SMA antibody, 
developed with DAB and counterstained with haematoxylin. A. healthy biopsy tissue, 
and B. asthmatic biopsy tissue with smooth muscle “block” staining used an internal 
positive control. Arrow identifies a line of myofibroblast-like cells immediately below 
the RBM. E- Epithelium; E(d)- Epithelium (denuded); LP- Lamina Propria; R-RBM; 
S- Smooth muscle; V- vessel. Scalebar - 100µm.
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Figure 3.5 Frequency of α-SMA immunopositive fibroblast-like cells in 
healthy and asthmatic bronchial biopsy tissue. Data points represent 
percentage of positive cells in lamina propria area to depth of 100µm from basement 
membrane, in 3 sections from each sample. Healthy mean ± SEM = 5.593 ± 0.714; 
Asthmatic mean ± SEM = 9.164 ± 1.037; p<0.05 (n=6 healthy & n=8 asthmatic). 
 
 
 
 
 
 
 
 
 
 
 
 Gaynor A. Campbell 
  69 
3.3.3   Tenascin C immunoreactivity 
Tenascin C expression has been reported in the RBM of asthmatics during 
“active” remodelling as assessed following segmental allergen challenge. De 
novo deposition has been suggested as a marker of EMTU re-activation and 
subsequent remodelling in asthmatic lung.  
 
A single section from each biopsy was immunostained with an anti-tenascin C 
antibody and total immunoreactivity scored on a scale from 0-3. Tenascin C 
immunoreactivity was seen in the RBM against the true basement membrane 
as expected. Expression was not significantly different between groups as 
assessed by unpaired t-test (Figure 3.6). Both healthy and asthmatic tissue 
showed a range of staining intensity, however no asthmatic samples scored 0 
(no staining) compared with 2 healthy samples, indicating possible increased 
basal levels of repair and regeneration in asthmatic tissue. 
 
3.3.4   Transforming Growth Factor β-2 immunoreactivity 
It has been reported that asthmatic lung tissue shows increased TGF-β2 levels. 
Increased TGF-β2 in the asthmatic lung may be an indicator of fibrotic and/or 
anti-inflammatory activity. Several studies report an increase in TGF-β2 levels 
following allergen challenge, while TGF-β1 levels remain unchanged. 
 
A single section from each biopsy was probed with a TGF-β2 polyclonal 
antibody and scored from 0-3. In this study, TGF-β2 was localised primarily to 
the epithelial layer and smooth muscle bands, with limited scattered cell 
positivity in the lamina propria in both healthy and asthmatic subjects 
(Figures 3.7 & 3.8).  There was no significant difference in TGF-β2 score in 
either the epithelium or smooth muscle compartments (Figure 3.9), or the 
lamina propria (data not shown). Figure 3.10 shows the frequency distribution 
of total (epithelium + smooth muscle + lamina propria) TGF-β2 scoring of 10 
healthy and 12 asthmatic biopsy samples. There is a trend towards increased 
TGF-β2 scoring in the asthmatic group that is not statistically significant.  
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Figure 3.6 Tenascin-C immunoreactivity score of healthy and asthmatic 
biopsy tissue. 5µm tissue sections were immunostained with a monoclonal tenascin 
C antibody, developed with DAB substrate and counterstained with haematoxylin. 
Images were taken with a Spot-32 camera and scored blindly in 3 independent 
screenings. Healthy mean ± SEM= 1.600 ± 0.371; Asthmatic mean ± SEM= 1.917 ± 
0.259; p>0.05. 0= no staining, 1=mild, 2= moderate, 3= intense immunostaining. 
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Figure 3.7 TGF-β2 immunoreactivity in healthy bronchial biopsy tissue. 
5µm sections were probed with a polyclonal TGF-β2 antibody, developed with DAB 
substrate and counterstained with haematoxylin. Images were taken with a Spot-32 
camera and analysed. Epithelial staining intensity scored as A=0, B=1 mild, C=2 
moderate and D=3 intense. E- Epithelium; LP- Lamina propria; R- RBM; S- Smooth 
muscle.  Scalebar  - 50µm.  
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Figure 3.8 TGF-β2 immunoreactivity in asthmatic bronchial biopsy 
tissue. 5µm tissue sections were incubated with a polyclonal TGF-β2 antibody, 
developed with DAB substrate and counterstained with haematoxylin. Images were 
taken with a Spot-32 camera and analysed. Epithelial staining intensity scored as 
A=0, B=1, C=2 and D=3. E- Epithelium; LP- Lamina propria; R- RBM; V- Vessel. 
Scalebar  - 50µm. 
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Figure 3.9 TGF-β2 immunoreactivity scores of epithelial and smooth 
muscle bronchial tissue compartments. Tissue sections were scored blindly on 
a scale from 0-3 as for Tn-C.  Healthy mean± SEM: epithelium=1.40±0.305, lamina 
propria=0.700±0.152, smooth muscle= 1.20±0.133. Asthmatic mean ± SEM: 
epithelium= 1.58±0.358, lamina propria= 0.9167± 0.1930, smooth muscle = 1.46± 
0.215. Unpaired t-test showed no significant difference. 
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Figure 3.10 Frequency of total TGF-β2 score distribution. Total of 
epithelium, lamina propria and smooth muscle scores for each sample, shown as the 
number of samples (frequency) to attain each total score. A trend towards increased 
asthmatic total score, and therefore biopsy immunoreactivity, is apparent.  
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3.3.5   TGF-βReceptor III (TβRIII) 
TGF-β2 has low binding affinity for the TβRI - TβRII hetero-dimer receptor 
complex that facilitates signal transduction. In contrast to other isoforms, 
TGF-β2 requires the TβRIII receptor (betaglycan) to present the TGF-β2 
dimer to the signalling complex. 
 
A single section from each biopsy was probed with a polyclonal TβRIII 
antibody and examined (Figure 3.11). Positive immunoreactivity was observed 
primarily in the epithelium, with scattered weak staining in the lamina propria 
and smooth muscle, similar to that reported by Balzar et al. (Balzar et al., 
2005a). No difference was observed between healthy and asthmatic samples. 
 
3.3.6   Correlation of TGF-β2 and remodelling phenomena 
TGF-β2 is a pro-fibrogenic cytokine, and expression has been linked to 
increased AWR in asthmatics (Chu et al., 2004). To investigate whether this 
finding was repeated in this sample cohort, Spearman’s rank correlation 
coefficient (RS) was calculated for all samples, assessing correlation between 
epithelial, lamina propria, smooth muscle and total TGF-β2 scores with RBM 
thickness, myofibroblast frequency and TnC expression. The RS values for 
each calculation are shown in Table 3.1. There were no statistically significant 
associations between TGF-β2 and remodelling, with one exception: healthy 
epithelial TGF-β2 scores associated with myofibroblast frequency, p=0.024, 
RS=-0.771. Asthmatic lamina propria TGF-β2 and myofibroblast frequency 
approached significance at p=0.057 and RS=-0.617. Following on from the 
work of  Brewster et al. (Brewster et al., 1990), the inter-relation betweeen 
RBM thickness and myofbroblast frequency was assessed, shown in a scatter 
plot in Figure 3.12. Significant correlation was not found in this sample cohort, 
however clustering of samples by disease status is apparent.
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 TGF-β Receptor III expression in bronchial biopsy tissue. 5µm 
sections of healthy and asthmatic biopsy tissue were immunostained with anti-
TβRIII, counterstained with haematoxylin. A representative image taken using a Spot 
camera is shown. Scalebar  - 100µm. 
 
Table 3.1 Spearman Rank (RS) correlation statistics. Remodelling markers 
and TGF-β2 score were analysed together in asthmatic (red) and healthy (blue) tissue.  
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Figure 3.12 RBM thickness and myofibroblast frequency correlation. 
Asthmatic (red) and healthy (blue) scores were plotted. Spearman rank correlation 
analysis indicated no significant association between these variables, although 
clustering of each phenotype is apparent. Healthy p=0.401, RS=0.142; Asthmatic 
p=0.303, RS= -0.187. 
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Figure 3.13 TGF-β2 expression scores of epithelium, lamina propria and 
smooth muscle plotted against RBM thickness, myofibroblast frequency 
and tenascin-C expression. No statistically significant differences between 
healthy and asthmatic samples were observed, but a minor trend of healthy samples 
grouping on the lower end of the scale, and asthmatic towards the upper is apparent. 
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Scatter plots of TGF-β2 scores (for individual tissue compartments) vs. 
remodelling scores are shown (Figure 3.13). Although not significant, a trend 
towards clustering of healthy samples to lower scale, and asthmatic to the 
upper is apparent, suggestive of transient increases in TGF-β2 expression in 
asthmatic tissue. 
 
3.4   Summary 
This study assessed bronchial biopsy tissue from 12 mildly asthmatic and 10 
healthy individuals, for remodelling phenomena and TGF-β2 expression. 
Additionally, association of TGF-β2 expression with remodelling features was 
investigated. Evaluation of biopsy tissue was undertaken to prime future in-
vitro work using primary bronchial cells, to inform whether mildly asthmatic 
EMTU cells have an altered phenotype and could thus produce different 
responses in culture. 
 
For RBM thickness measurements results were calculated from 3 independent 
evaluations of each image. Intra-observer variation was below 8%, similar to 
that reported by Chu et al. Asthmatic samples displayed a significantly thicker 
RBM compared with healthy control tissue, similar to and in agreement with 
other published studies (Chu et al., 1998; James et al., 2002; O'Shaughnessy 
et al., 1997) 
 
Frequency of myofibroblast differentiation was determined in lamina propria 
cells. Asthmatic tissue had a statistically significant increase in myofibroblast 
frequency compared to healthy tissue.  
 
Tenascin C expression levels were not significantly different between healthy 
and asthmatic tissue. However, none of the asthmatic samples scored 0, 
suggesting a greater incidence of stress/injury and therefore subsequent TnC 
response in that group. 
 
TGF-β2 expression was evaluated in a single section of each biopsy using a 
polyclonal antibody following sodium citrate antigen retrieval. Expression in 
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separate anatomical “compartments” was scored, comprised of the epithelium, 
lamina propria and smooth muscle. There were no statistically significant 
differences in these samples, however a trend towards increased total TGF-β2 
expression levels in asthmatic tissue was observed. 
 
In correlation analyses, only epithelial TGF-β2 and myofibroblast frequency 
expression in healthy samples reached statistical significance. Asthmatic 
lamina propria TGF-β2 expression and myofibroblast frequency approached 
significance at p=0.057.  
 
In summary, measurable statistically significant evidence of remodelling was 
shown in mildly asthmatic tissue used in this study, therefore the null 
hypothesis that there is no significant difference in measures of AWR between 
healthy and asthmatic bronchial biopsy tissue can be rejected.  
3.5   Discussion 
Airway wall remodelling (AWR) encompasses alterations both in the 
extracellular matrix and cells resident in the airway, and contributes to the 
symptom persistence and decrease in respiratory function observed in many 
asthmatics (Bai, 2009). AWR is largely untreated by current medications and 
as such, understanding of the processes that drive AWR may lead to improved 
treatment options. Reactivation of the epithelial-mesenchymal trophic unit 
has been posited by some researchers as an initiator of AWR (Holgate et al., 
2004).  This study aimed to quantify commonly held markers of the 
remodelling process: reticular basement membrane (RBM) thickness, 
myofibroblast differentiation and tenascin C (TnC) deposition, in bronchial 
biopsy tissue. The pro-fibrotic, anti-inflammatory cytokine TGF-β2 was 
investigated as it is transiently upregulated in allergic asthma, and may also be 
a contributory factor in AWR processes.  
 
RBM thickening is the typical measure of AWR in asthma. Investigating the 
hypothesis that AWR led to thickened airway walls and thus decreased 
respiratory function, a number of studies showed RBM thickness correlated 
with increased overall thickness of the bronchial wall measured by high-
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resolution computerised tomographic scanning (James et al., 2002; Kasahara 
et al., 2002). Other studies have shown a positive correlation between 
increasing RBM thickness and inhaled glucocorticoid use (indicating increased 
severity of asthma), with greater increases demonstrated in atopic compared 
with non-atopic asthmatics (Amin et al., 2000). Whether RBM thickness may 
be used as a marker of asthma severity is a point for debate. Several groups 
have shown a positive correlation between increased RBM thickness and 
decreased FEV1% predicted(Bourdin et al., 2007; Hoshino et al., 1998b; Shiba 
et al., 2002) whilst others show no association(Chu et al., 1998; Hoshino et 
al., 1998a; Liesker et al., 2009; Tillie-Leblond et al., 2008). The disparity 
between groups may be explained by the use of single biopsies from different 
levels of the bronchi, the grade of asthmatic severity used (mild vs. moderate 
vs. severe), and the criteria used to to determine these classifications. Different 
methods used in measuring RBM thickness may also play a role. 
 
Two methods of calculating RBM thickness are predominant in the literature. 
Sullivan et al. devised a multiple point-to-point method of measurement, 
whereby the top and bottom of the RBM are marked then multiple top-to-
bottom measurements made along the length of the selection (Sullivan et al., 
1998). Wilson & Li selected whole areas of RBM and performed area/length 
calculations (Wilson and Li, 1997). To ensure their method was robust, Wilson 
& Li used transmission electron microscopy (TEM) measurements as a “gold 
standard” for comparative purposes.  Use of TEM was not practical for this 
study due to the requirement for multiple biopsies for specialised sample 
preparation; with a single biopsy available per patient,  wax-embedding tissue 
allowed both histological and immunohistochemical analyses. A comparative 
study found both methods produced similar results, as long as sufficient 
length of RBM was included in the analysis (Bourdin et al., 2007). The point to 
point method of Sullivan et al. was chosen for this study as it was marginally 
less reliant on biopsy tissue with continuous straight lengths of RBM to 
generate reliable data.  
 
All asthmatic biopsy samples used in this study were obtained from mild, 
steroid-naïve asthmatic subjects. Asthmatic RBM was significantly thicker 
 Gaynor A. Campbell 
  82 
compared with healthy samples, even within the small sample size. Studies 
using similarly designated tissue, reported results within comparable limits. 
Chu et al. report RBM thickness increasing with severity of disease, from 
control bronchial biopsy tissue at 5.2µm, mild asthmatic 5.5µm, to moderate 
and severe at 6.8µm and 6.5µm respectively, although as in this study each 
subset contained a wide range of measurements (Chu et al., 1998). It is of note 
that the severe asthmatic mean was marginally less than the moderate. This 
may be attributable to the use of oral steroids in this subset, which can exert a 
small reducing effect on RBM thickness during treatment, as demonstrated in 
other studies (Shiba et al., 2002). RBM thickness appears fairly fixed by 6 
years of age in asthmatics, and so variability in age of study participants 
should not affect results (Bush, 2008). RBM thickening is not confined to 
asthmatic lung and has been quantified in eosinophilic bronchitis, allergic 
rhinitis and cystic fibrosis (Brightling et al., 2002; Hilliard et al., 2007). It is 
unknown whether the mechanism of thickening is the same. That it is 
identifiable in other disease states points to it being a response to bronchial 
stress. It has been suggested that RBM changes may protect from 
bronchospasm (Milanese et al., 2001).  
 
Myofibroblasts are fibroblast-like cells with increased matrix synthesis 
capacity and augmented contractile features. They are associated with tissue 
repair and fibrosis and are the main matrix-producing cell in tissue repair 
events throughout the body (Brewster et al., 1990). The physical strain of 
asthma attacks and increased TGF-β isoform production provide an ideal 
environment for fibroblast differentiation, which requires both active TGF-β 
exposure and mechanical strain (Desmoulière et al., 1993). Myofibroblasts 
were quantified in a region of tissue limited to 100µm depth from the 
basement membrane. This method was selected as a consistent way to 
differentiate collagen deposition capacity in bronchial biopsy tissue 
(O'Shaughnessy et al., 1997). The statistically significant increased 
myofibroblast representation amongst the cell population in the asthmatic 
samples found here is significant due to the increased matrix secretory 
capacity of these cells. The origin of myfibroblasts in subepithelial fibrosis is 
not defined.  The majority differentiate from resident fibroblasts, but these 
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may be supplemented by migrating smooth muscle cells and circulating 
fibrocytes that differentiate into myofibroblast-like cells (Hinz et al., 2007a). 
Increased secretion of cytokines by myofibroblasts has been identified, and 
may contribute to the continual activation state of cells resident in the 
asthmatic EMTU and beyond (Ward et al., 2008). Previously published work 
used BAL fluid to assay MMP and TIMP levels to evaluate possible collagen 
turnover, however BAL fluid was not available for this study. 
 
The dynamic deposition pattern of glycoprotein tenascin C at points of tissue 
injury/stress make it a useful marker of remodelling activity in the asthmatic 
bronchi. In a murine model of lung epithelial cell injury, Tn-C was increased at 
day 1 after injury, returning to baseline by day 3, confirming the limited 
temporal increase after epithelial injury of this protein (Snyder et al., 2009). 
In human tissue, Tn-C was increased in asthmatics at baseline (Flood-Page et 
al., 2003), and also significantly increased 24h after segmental allergen 
challenge in asthmatics (Phipps et al., 2004a). In this study there was no 
significant difference between healthy and mild asthmatic biopsy tissue. All 
asthmatic samples were scored above background, unlike healthy tissue 
samples. It may be hypothesised that positive immunoreactivity in healthy and 
asthmatic samples is indicative of remodelling in some form being part of 
healthy lung homeostasis. However, as only a single section was scored from 
each biopsy, this cannot be considered indicative of the lung tissue.  
 
Remodelling may be driven by increased TGF-β activity in the asthmatic lung. 
An investigation into TGF-β isoform expression in healthy and asthmatic 
biopsy tissue showed TGF-β2 to be the predominant isoform, localised 
primarily to the epithelium with limited expression in smooth muscle. TGF-β2 
was also the only isoform to be elevated in asthmatic tissue (Balzar et al., 
2005b). In  BAL fluid, Batra et al. found TGF-β2 expressed at slightly higher 
levels at baseline in healthy controls compared to atopic asthmatics. Allergen 
challenge led to a large spike in TGF-β2 levels at 24h in asthmatic subjects that 
was not seen in healthy controls. TGF-β1 levels also spiked in asthmatics, but 
in all cases TGF-β1 levels were consistently lower than TGF-β2, at all 
timepoints (Batra et al., 2004). The results in that study did not reach 
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significance, however there was a trend towards increasing TGF-β2 expression 
in the asthmatic tissue samples. These results were echoed here, whereby a 
general trend towards increased TGF-β2 expression was observed but did not 
reach statistical significance. All the asthmatic tissue was phenotypically mild 
and steroid naïve; Balzar et al. showed TGF-β2 increasing in line with asthma 
severity, whilst other groups have identified increasing TGF-β1 levels 
proportional to asthma severity in biopsy and lavage respectively (Minshall et 
al., 1997; Tillie-Leblond et al., 1999) . Results shown here may be limited by 
the mild tissue phenotype used; the inclusion of moderate/severe asthmatic 
tissue samples may produce statistically significant increases in TGF-β2 
expression. 
 
Increased phosphorylated Smad2 protein has been described in the asthmatic 
epithelium at baseline (Sagara et al., 2002) and after allergen challenge 
(Phipps et al., 2004b). Upregulation of TGF-β receptor signalling could be 
partly explained by the finding of Nakao et al., who illustrated decreased basal 
Smad7 (a negative regulator of the TGF-β-Smad signalling pathway) 
expression in the epithelial layer in asthmatic biopsy tissue (Nakao et al., 
2002). The reduction in downregulatory/control capacity this could effect 
exemplifies the multi-layered mechanisms by which TGF-β activity may be 
modulated in the asthmatic airway. Results such as those cited above indicate 
there may be increased TGF-β activity in the asthmatic lung that exclude the 
need for concomitant increases in active TGF-β2 levels.  
 
Active TGF-β2 must bind to specific receptors and signal intracellularly to 
produce downstream effector functions. TGF-β2 presentation to the TβRI-
TβRII heterodimer TβRIII expression was assessed due to the role of this 
molecule in TGF-β2 receptor binding. No differences were found between 
healthy and asthmatic tissue expression levels in this study. Animal studies 
have identified alterations in TβRIII expression induced by periods of hypoxia, 
however there is no published data on TβRIII expression in asthma (Vicencio 
et al., 2002). It has been reported that a splice variant of TβRII (TβRII-B) is 
sufficient for TGF-β2 signalling so bypassing the requirement for Tβ
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however commercial antibodies were unavailable (del Re et al., 2004b; Rotzer 
et al., 2001). 
 
The causal relationship between the AWR features discussed earlier and 
asthmatic disease manifestations is broadly unknown. Delineation of these 
relationships relies on correlation between remodelling phenomena and other 
features of asthmatic disease. Increased RBM thickness has been positively 
correlated with AHR (Hoshino et al., 1998a) and with frequency of asthma 
attacks (Evans et al., 1999). However, other groups have found asthma 
exacerbations predict decline in lung function, and not the extent of  
remodelling (O'Byrne et al., 2009). AHR measures were not taken from all 
subjects whose tissue was acquired for inclusion in this study, and asthma 
exacerbation frequency was very low in the mild steroid naïve asthmatic 
subjects used, with no exacerbations in the previous month as a standard 
minimum. Regarding TGF-β, the majority of published data concerns the -β1 
isoform, and increased TGF-β1 expression in the submucosa has been 
identified. The same study also highlighted increased sub-epithelial fibrosis 
(RBM thickness) correlated to increased asthma severity (Minshall et al., 
1997), again indicating remodelling may directly affect AHR.  Sagara et al. 
established that TGF-β specific signalling via p-Smad2 was increased in 
asthmatic bronchial tissue over healthy controls, correlated with increases in 
RBM thickness (Sagara et al., 2002). Although correlation analyses in this 
study did not lead to any significant associations, there was a clear separation 
of the samples into their respective groups when remodelling scores were 
plotted against TGF-β2 expression. Again, statistical significance may only be 
reached with increased sample number, possibly including asthmatic biopsy 
tissue from moderate/severe phenotypes. 
 
The studies discussed above add weight to the hypothesis that TGF-β2 can 
promote remodelling responses in asthma. It is clear from results presented 
here that mild asthmatic tissue undergoes remodelling processes. Cells 
derived from such subjects may show altered responses compared with 
healthy controls in-vitro, to be investigated in further chapters. 
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Regarding the mild asthmatic phenotype studied, it would be possible to 
differentiate between “inactive” and “active” allergic asthma through the 
enumeration of mast cells in the tissue. Tissue and BAL fluid from “active” 
asthmatics shows increased mast cell infiltration, however with the mild 
phenotype accessed a significant difference may not be identifiable.   
 
The majority of TGF-β2 immunoreactivity in this study was found in the 
epithelial layer, but other studies have focused on TGF-β levels in specific cell 
populations to identify drivers or promotors of remodelling. Such work could 
be repeated in this sample cohort, perhaps  through identification of co-
localization of TGF-β2 expression with activated eosinophils, identified by 
EG2 immunoreactivity. Additionally, in-situ hybridisation to identify which 
cells are actively producing TGF-β2, or laser capture microdissection of cell 
populations followed by RT-PCR may provide additional information on TGF-
β2 and it’s downstream effects.  
 
 
 
 Gaynor A. Campbell 
  87 
 
Chapter 4: Expression and activation of TGF-β2 following 
experimental injury of human bronchial epithelial cells 
 
4.1   Overview 
The upper respiratory tract functions to warm, moisten and filter inhaled 
environmental factors from air before it reaches the lower respiratory tract. 
Despite this, the bronchial epithelium is challenged by a proportion of 
environmental matter, and acts to maintain tissue homeostasis and 
appropriate barrier function through the mucociliary escalator, epithelial 
repair and immunomodulation. TGF-β2 is transiently upregulated at some 
sites of epithelial injury, promoting wound repair. Dysfunctional repair and 
incomplete resolution of inflammation are thought to occur in the asthmatic 
epithelium leading to airway wall remodelling (AWR). Increased TGF-β2 
expression levels have been identified in the asthmatic epithelium following 
segmental allergen challenge in human bronchial biopsy studies (Batra et al., 
2004), and in-vitro studies have demonstrated the increased sensitivity of 
asthmatic fibroblasts to TGF-β2 mediated myofibroblast transition effect 
(Wicks, 2006). Myofibroblasts go on to increase extracellular matrix molecule 
production, contributing to remodelling. Increased TGF-β2 production by the 
bronchial epithelium, possibly arising from a non-resolving wound response, 
could therefore drive some aspects of AWR. Expression and activation of TGF-
β isoforms are tightly regulated processes both temporally and spatially 
however,  
 
House dust mite is a prominent source of environmental allergens in the 
western hemisphere, present at levels sufficient for sensitization (Platts-Mills 
et al., 1992). Approximately 21 allergens have been identified from house dust 
mite species thus far and at least 12 have been isolated from the European 
house dust mite, Dermatophagoides pterronysinus (Thomas et al., 2002). 
Many of these allergens have proteolytic activity. Group 1 allergen, Der p 1, 
was identified in 1980  as a cysteine protease (Chapman and Platts-Mills, 
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1980), with sequence homology to papain (Chua et al., 1988). Subsequent 
purification identified allergens including Der p 3 and 6, with serine protease 
activity (Stewart et al., 1989; Yasueda et al., 1993). The proteolytic activity of 
these allergens can affect epithelial permeability through degradation of the 
tight junction protein occludin (Wan et al., 2001; Wan et al., 1999), and can 
activate epithelial cells by cleavage of protease activated receptor-2 (PAR-2) 
(Kauffman et al., 2006). 
 
Latent TGF-β1 can be activated by several proteases in-vivo, including the 
serine proteases plasmin (Nunes et al., 1997),  tryptase (Tatler et al., 2008), 
chymase, neutrophil elastase  and thrombin (Taipale et al., 1992; Taipale et 
al., 1995), and the cysteine protease cathepsin B (Gantt et al., 2003). Abe et al. 
presented evidence of latent TGF-β1 activation in-vitro in the presence of cells 
by the cysteine protease calpain (Abe et al., 1998). An investigation into 
increased TGF-β activation following glucocorticoid treatment identified 
increased cathepsin-B protein secretion (a cysteine protease) by osteoblast 
cells as a possible mechanism; osteoblast conditioned medium alone was 
sufficient to activate latent TGF-β1 (Oursler et al., 1993).  Less is known in 
terms of TGF-β2 activation by proteases. In–vitro, Dallas et al. established the 
preferential activation of recombinant latent TGF-β2 by the serine protease 
prostate specific antigen, from primary human cells (Dallas et al., 2004). 
These findings are of interest in asthma as the major dust mite allergen Der p 1 
is a cysteine protease, and Der p 3, 6 and 9 are serine proteases. Furthermore, 
it was recently shown that purified Der f 1 (from the North American dust mite 
Dermatophagoides farinae), can proteolytically cleave and activate latent 
TGF-β1 (Nakamura et al., 2009). However, the effect of European house dust 
mite allergens with protease activity on latent TGF-β activation has not been 
investigated.  
 
4.2   Aims and Hypothesis 
The aims of this chapter are: 
1. To characterise the proteolytic activity of commercial HDM 
preparations  
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2. To investigate whether these HDM preparations activate native 
latent TGF-β2 
3. To assess whether HDM exposure leads to increased expression of 
TGF-β2 by transformed and primary bronchial epithelial cells 
 
It is hypothesised that the proteolytic activity of HDM can activate latent TGF-
β2 produced by human bronchial epithelial cells. 
 
4.3  Results 
4.3.1  Commercial amino acid enzyme substrate is cleaved by both 
serine and cysteine proteases 
Prior to performing experimental work with HDM preparations, the 
proteolytic cleavage susceptibility of the selected enzyme substrate was 
confirmed. The amino acid substrate N-benzoyl-Phe-Val-Arg-p-nitroanilide-
hydrochloride (NBPVANA) has been reported to be sensitive to both serine 
(trypsin) and cysteine (papain, Der p 1) protease activity (Sehgal, 2005). 
NBPVANA cleavage produces a colorimetric product measurable by 
absorbance at 405nm.  
 
The NBPVANA substrate was incubated with trypsin (3U/ml) or papain 
(200mU/ml) at 37°C for 2 hours, and 405nm absorbance readings taken at 
20min intervals, following the protocol of Sehgal. Absorbance readings were 
plotted against time, and the reaction progression curves show both trypsin 
(serine) and reduced papain (cysteine) proteolytically cleaved the NBPVANA 
substrate. Trypsin reached a reaction plateau by 20 min, with an activity rate 
of  3.86µM/min in this time period. Papain showed a rate of substrate 
breakdown of 1.53µM/min over the same time.  Class-specific protease 
inhibitors of trypsin (PMSF) and papain (E64) were included to confirm their 
efficacy in excess, while unreduced papain (no DTT reduction) showed no 
activity (Figure 4.1).  
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Figure 4.1 Reaction progression curves of substrate cleavage by a serine 
or cysteine protease. NBPVANA substrate (125µM ) was incubated with serine 
protease trypsin (3U/ml) or cysteine protease papain (200mU/ml), with and without 
class-specific inhibitors PMSF (1mM) and E64 (10µM). Unreduced papain showed no 
activity, confirming reduction of the thiol group is essential for cysteine protease 
activity.  
 
4.3.2  Serine and cysteine proteolytic profiles of commercial house 
dust preparations 
Following confirmation of substrate suitability, a commercially available HDM 
extract (HDM SPT) (ALK-Abello, Netherlands) was assessed in the assay. The 
extract is used in skin prick testing and is therefore expected to contain the 
major allergens of Dermatophagoides pterronysinus. An initial experiment 
using 100,000 and 10,000U/ml showed that the lower concentration had very 
limited proteolytic activity. The extract was therefore used in the assay 
undiluted, at 100,000U/ml as this produced progression curves comparable to 
the concentrations of other enzymes selected. Units given are not indicative of 
protease activity units, instead they are a measure of skin prick test 
responsiveness as determined by the manufacturer. Protease activity and 
allergen level data is not supplied or available for this product.   
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HDM SPT continous rate assays show that activity was not affected by 
reduction (Figure 4.2). Incubation with class-specific protease inhibitors 
showed that HDM SPT has serine protease activity. Combined protease 
inhibitor cocktail (PIC) inhibited all activity, as did the serine protease 
inhibitor PMSF alone, with no appreciable protease activity remaining. 
Cysteine protease inhibitor E64 showed no effect. Substrate breakdown rate 
for reduced HDM SPT was 1.88µM/min, and for unreduced HDM SPT was 
1.81µM/min in the linear phase of the reaction. 
 
Comparison of HDM SPT extract activity with cysteine protease papain 
confirmed that reduction was not necessary for HDM SPT proteolytic activity 
(Figure 4.3).  
 
The lack of measurable cysteine protease activity was unexpected as Der p 1, 
reportedly the most abundant allergen in house dust mite, is a cysteine 
proteae with structural homology to papain. It is possible that serine protease 
activity outweighed cysteine protease activity simply because there was a 
greater amount of serine protease activity present in the preparation. The 
manufacturers do not divulge data on the mixture/proportion of allergens 
present. Allergen levels can vary widely in preparations from different 
suppliers (Ford et al., 1985). 
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Figure 4.2 Reaction progression curves of substrate cleavage by a 
commercial HDM extract. HDM extract (100000U/ml) was incubated with and 
without serine (PMSF- 1mM), cysteine (E64- 10µM) and a complete protease 
inhibitor cocktail (PIC-20µl stock) prior to the addition of 125µM NBPVANA 
substrate. Unreduced HDM extract maintained over 95% activity, revealing minimal 
contribution from cysteine proteases.  
 
 
 
Figure 4.3 Comparison of papain and HDM extract proteolytic activity. 
Reaction progression curves of substrate cleavage over time by HDM extract 
(100,000U/ml) and cysteine protease papain (200mU/ml). Unreduced papain shows 
no activity, but unreduced HDM extract maintains a similar activity profile to the 
reduced sample. 
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The HDM SPT extract used in this study is a standardised mixture of allergens, 
however it does not bear much resemblance to environmental presentation of 
HDM. Alternatively, mite stocks can be cultured in the lab, where they secrete 
major allergens into the culture media. Lyophilised spent culture media, 
consisting of a mixture of HDM fecal pellets, eggs, nymphs and other variables  
(HDM FP) was acquired for use in this study (Indoor Biotechnologies Ltd, 
Warminster, UK). This product is for research use only and is not used in any 
clinical setting. HDM FP was reconstituted at 1mg/ml in solution, although a 
small proportion of the matter proved insoluble.  
 
Unreduced and reduced HDM FP showed similar proteolytic activity of 
3.16µM/min and 2.97µM/min respectively, in the linear phase of the reaction 
between 20-40min (Figure 4.4). The reaction plateaued at 6omin. HDM FP 
incubated with cysteine protease inhibitor (E64) did not differ from HDM FP 
alone. Serine protease inhibitor PMSF at 1mM slowed the rate of reaction to 
1.84µM/min, but by 2h the reaction reached the plateau. Complete protease 
inhibitor cocktail (PIC) completely abrogated all protease activity.  
 
HDM SPT and HDM FP were then assayed together. The HDM preparations 
showed almost identical proteolytic profiles (Figure 4.5). Breakdown of 
NBPVANA substrate in the linear phase  (20-40min) was 3.37µM/min by 
HDM SPT and 3.6µM/min by HDM FP. The reaction plateaued at 60min, and 
protease inhibitor cocktail blocked activity.  
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Figure 4.4 Serine and cysteine proteolytic activity of HDM fecal pellet 
solution. Reaction progression curves of NBPVANA substrate breakdown over time 
by HDM FP (1mg/ml saturated). Inhibitors of serine (PMSF- 1mM) and cysteine 
(E64- 10µM) activity were included, and protease inhibitor cocktail (PIC). 
 
 
Figure 4.5  HDM SPT extract and HDM FP proteolytic activity.   
HDM SPT (100000U/ml) and HDM FP (1mg/ml) were reduced prior to addition of 
125µM NBPVANA substrate. Protease inhibitor cocktail was effective in both HDM 
SPT and HDM FP samples.  
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A single substrate concentration of 125µM was used in all reactions, and HDM 
preparations contain a mixture of enzymes, so the results were not suitable for 
Michaelis-Menten analysis to determine reaction kinetics.  
 
This section presented evidence for proteolytic activity in 2 different HDM 
preparations.  Both preparations showed similar serine protease activity levels 
on the substrate. The quantity of PMSF used (1mM) was insufficient to 
entirely block serine protease activity of HDM FP though, and this may be due 
to greater serine activity, or possibly due to a different class of protease. There 
was no measurable cysteine protease activity in either extract. This may be due 
to low levels of Der p 1 in the preparations used.  
 
4.3.3  Activation of LTGF-β2 by proteolysis in an acellular 
environment 
It was hypothesised that proteolytic activity of HDM extract could activate 
latent TGF-β2. Proteolytic activation in-vivo is often dependent on cell- or 
matrix-association of the latent cytokine, as for the plasmin activation of 
LTGF-β1. However, initial assessments of proteolytic activation were 
performed in cell-free conditioned medium culture supernatant containing 
native latent TGF-β2. LTGF-β2 was not available from a commercial source. 
Omitting cells ensured no cell-mediated effects would interfere, for example 
through upregulation of TGF-β2 production or secretion of cellular proteases 
in response to HDM stimulation. The experiments in this section utilised cell-
free conditioned medium (CM) from the SV-40 transformed bronchial 
epithelial cell line 16HBE14o- as a source of TGF-β2 protein. These cells 
constitutively secrete latent and active TGF-β2. TGF-β2 protein levels were 
assessed by ELISA.  
 
Serum-free conditioned medium from 16HBE14o- cells was collected at 24h, 
and exposed to different protease preparations for 24h at 37°C, in order to 
analyse the ability of HDM proteases to activate latent TGF-β2 (Figure 4.6). 
HDM SPT extract was used at 2000U/ml (Salib et al., 2005), HDM FP at 
20µg/ml, papain at 100mU/ml and plasmin at 2U/ml (Lyons et al., 1990). 
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Levels of active TGF-β2 were not affected by protease incubation with the 
exception of papain-exposed samples that showed complete loss (degradation) 
of the active cytokine.  
 
Levels of total TGF-β2 (active + latent) were analysed in CM by heating to 
80°C for 6mins prior to assaying, to investigate degradation of LTGF-β2 due to 
protease activity (Figure 4.7). HDM FP degraded a small but significant 
proportion (17%) of the native LTGF-β2, and papain degraded  the majority of 
both active and latent TGF-β2.  
 
 
Figure 4.6 Active TGF-β2 in 16HBE14o- conditioned media following 24h 
incubation with protease preparations. CM was assayed by ELISA following 
incubation with HDM SPT (2000U/ml), HDM FP (20µg/ml), papain (100mU/ml) or 
plasmin (2U/ml). Data were analysed by one way ANOVA followed by Dunnett’s test 
(n=3, ***=p<0.005). 
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Figure 4.7 Total TGF-β2 in 16HBE14o- conditioned media following 24h 
incubation with protease preparations. CM was heat treated and assayed by 
ELISA following incubation with HDM SPT (2000U/ml), HDM FP (20µg/ml), papain 
(100mU/ml) or plasmin (2U/ml). Data were analysed by one way ANOVA followed by 
Dunnett’s test (n=3, *=p<0.05 ***p<0.005). 
 
Although there was no significant increase in TGF-β2 activation, a decrease in 
total TGF-β2 was identified in HDM FP exposed samples. A comparison of 
active vs. total (latent + active) TGF-β2 levels showed no significant difference 
in between HDM preparation exposed and control levels with the exception of 
papain-exposed samples that were almost entirely degraded (Figure 4.8).  
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Figure 4.8 Percentage active TGF-β2 in 16HBE14o- conditioned media 
following 24h incubation with protease preparations. Assayed by ELISA 
following incubation with HDM SPT (2000U/ml), HDM FP (20µg/ml), papain 
(100mU/ml) or plasmin (2U/ml). Data were analysed by one way ANOVA followed by 
Dunnett’s test (n=3, *** p<0.005). 
 
This section showed that HDM preparations and plasmin did not activate 
native LTGF-β2 in a cell-free environment. The experimental procedure was 
then altered to investigate the effect of protease preparations on submerged 
16HBE14o- cultures TGF-β2 secretion and activation.  
  
4.3.4  Secretion and activation of TGF-β2 by confluent 16HBE14o- 
cell cultures following protease challenge 
Confluent 16HBE14o- cells were exposed to protease preparations for 24h at 
37°C, as in the CM study.  The supernatant was harvested and assayed by 
ELISA for both active and total TGF-β2. To ensure detectable levels of TGF-β2 
were present, cell challenge began 24h after the final media change, so media 
assayed was collected at 48h, and not 24h as the CM samples used in section 
4.2.2. Tryptase (15mU/ml) was also included in these experiments as it has 
been shown to activate cell-associated latent TGF-β1 at this concentration 
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(Tatler et al., 2008), and is secreted by mast cells in the asthmatic airway 
(Woodman et al., 2008) (Figure 4.9). 
 
Challenge of cultured cells rather than conditioned media with HDM 
preparations produced marked differences in levels of active TGF-β2. Papain 
again degraded TGF-β2 secreted, and is not shown here. A significant decrease 
(p<0.005) was observed in HDM FP exposed cultures. Challenge with tryptase 
led to a small but significant (p<0.05) increase in active TGF-β2. Similar levels 
of active TGF-β2 were measured in control cultures at 48h as seen in  the 24h 
cultures.  
 
A significant decrease in total TGF-β2 was observed in HDM SPT exposed 
cultures, and a greater decrease in HDM FP exposed cultures. Both tryptase 
and papain exposure resulted in significant increases in total TGF-β2 (Figure 
4.10). 
 
To identify increases in LTGF-β2 production and effects on active TGF-β2 
levels following protease exposure, the percentage of active TGF-β2 was 
calculated. Figure 4.11 shows percentage active TGF-β2 in HDM protease-
challenged 16HBE14o- cell cultures. HDM SPT exposure did not differ from 
control proportions (around 40%). HDM FP, tryptase and plasmin all showed 
a decreased proportion compared to control cultures, of 28%, 33% and 17% 
respectively. These results indicate that HDM FP may be degrading both active 
and latent forms of TGF-β2, although may also be affecting TGF-β2 secretion 
by cells. Tryptase and plasmin exposure increased TGF-β2 production by cells.  
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Figure 4.9 Active TGF-β2 secreted by confluent 16HBE14o- cultures 
following 24h protease exposure. Supernatant was harvested at 24h and assayed 
by ELISA following exposure to HDM SPT (2000U/ml), HDM FP (20µg/ml), tryptase 
(15mU/ml) or plasmin (2U/ml). Data were analysed by ANOVA followed by 
Dunnett’s test (n=3, *p<0.05, ***p<0.005). 
 
 
Figure 4.10 Total TGF-β2 secreted by confluent 16HBE14o- cultures 
following 24h protease exposure. Supernatant was harvested at 24h, heat 
treated and assayed by ELISA following exposure to HDM SPT (2000U/ml), HDM FP 
(20µg/ml), tryptase (15mU/ml) or plasmin (2U/ml). Data were analysed by ANOVA 
followed by Dunnett’s test (n=3, *p<0.05, ***p<0.005). 
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Figure 4.11 Percentage active TGF-β2 in confluent 16HBE14o- cell 
supernatant following 24h protease exposure. Supernatant was harvested at 
24h and assayed by ELISA following exposure to HDM SPT (2000U/ml), HDM FP 
(20µg/ml), tryptase (15mU/ml) or plasmin (2U/ml). Data were analysed by ANOVA 
followed by Dunnett’s test (n=3,*p<0.05,  **p<0.01, ***p<0.005).  
 
In summary, the proteolytic activity present in HDM preparations did not 
appear to activate native LTGF-β2 in the cell-associated environment. HDM 
SPT had no effect either on the activation of or the expression of LTGF-β2, 
while HDM FP exposure appeared to degrade TGF-β2 protein and may also 
downregulate TGF-β2 expression.  
 
4.3.5  Comparison of TGF-β2 secretion and activation by 16HBE14o-
cell cultures following injury or allergen challenge 
Injury to the epithelial layer in asthma may drive increased TGF-β2 
expression. The use of “scratch” assays has become the standard method of 
injury in bronchial epithelial culture (Howat et al., 2002; Thompson et al., 
2006). Confluent cultures are subjected to a scratch across the surface using a 
sterile pipette tip. This physical injury is intended to mimic the epithelial sheet 
shearing thought to occur during the acute asthmatic response. HDM extracts 
may contain variable levels of lipopolysaccharide (LPS), a Toll-like receptor 4 
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(TLR4)  ligand, but the proteolytically inactive allergen Der p 2 (concentrated 
in fecal pellets) can activate TLR4 in the absence of LPS (Trompette et al., 
2009). To confirm whether LPS exposure was sufficient to alter TGF-β2 levels 
in a protease-independent manner, LPS was added to cell cultures at a 
concentration of 100ng/ml as a control.  
 
Cell challenge began 24h after the final media change, so supernatant assayed 
was from a total 48h. A significant decrease (p<0.05) in active TGF-β2 was 
observed in HDM FP–exposed cultures, whereas HDM SPT did not differ from 
control. Scratch injury and LPS exposure did not significantly alter active 
TGF-β2 levels (Figure 4.12A). 
 
When total TGF-β2 levels were assayed, there was a significant increase in 
TGF-β2 in HDM SPT exposed and  scratch injured cultures. No difference 
compared with control cultures was seen following HDM FP or LPS exposure 
(Figure 4.12B). The increase in total TGF-β2 in scratch injured cultures 
suggests this method of injury provokes a wound healing response, and 
correlates with previously published work (Howat et al., 2002). 
 
The percentage of active TGF-β2 was calculated, to identify alterations in  the 
proprotion of active TGF-β2 present following HDM preparation exposure or 
injury (Figure 4.12C). HDM SPT and HDM FP exposure significantly 
decreased the proportion of active TGF-β2 present. HDM FP decreases are 
likely due to proteolytic degradation of the active and latent protein. A 
significant decrease was also observed in LPS exposed cultures, but there was 
no significant difference between scratch injured and control cultures.  
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Figure 4.12 TGF-β2 production by 16HBE14o- cells 24h following HDM 
exposure or experimental injury. Cells were challenged with HDM SPT 
(2000U/ml),  HDM FP (20µg/ml), LPS (100ng/ml) or scratch injury. Media was 
collected at 24h for assay by ELISA. A. Active TGF-β2, B. Total TGF-β2 in heat-
treated media and C. Percentage active TGF-β2 produced. Data were analysed by 
ANOVA followed by Tukey’s test (n=3, *p<0.05, **p<0.01, ***P<o.oo5).  
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 To summarise, HDM challenge did not lead to increased TGF-β2 activation in 
the transformed bronchial epithelial cell line 16HBE14o-. Therefore, the next 
set of experiments investigated TGF-β2 activation following allergen exposure 
using a more physiological model, consisting of healthy primary human 
bronchial epithelial cells grown at air-liquid interface (ALI).  
4.3.6  Secretion and activation of TGF-β2 by primary bronchial 
epithelial cells following injury or allergen challenge 
Primary human bronchial epithelial cells (HBEC), from 3 different donors, 
were seeded into polycarbonate membrane hanging inserts in 12 well plates 
and grown submerged until confluence. When cells had formed a confluent 
layer, the apical media was removed, allowing cell differentiation at the air-
liquid interface. All challenges took place after a minimum of 7 days culture at 
ALI, to allow apical-basal polarity to be established, mature tight junctions to 
form and for cells to differentiate to ciliated or goblet type. Culture at ALI 
provides a more physiological epithelial layer for in-vitro experiments than 
submerged culture (Kikuchi et al., 2004; Vanwetering et al., 2007).  
 
Cell challenge began 24h after the final media change to ensure detectable 
levels of TGF-β2 were present. The culture media assayed was therefore 
collected at a total of 48h, following 24h challenge. As HDM FP appeared to 
degrade TGF-β2, only HDM SPT was used in these experiments as an allergen 
challenge. Following 24h exposure to HDM SPT (2000U apically), scratch or 
LPS (100ng/ml basally), culture media was harvested and assayed by ELISA 
for both active and total levels of TGF-β2.  
 
Figure 4.13A presents data on active TGF-β2 production from the first donor 
(2F1578). HDM SPT exposure led to a significant increase in active TGF-β2, 
and scratch injury a slight increase (not significant). There was a decrease in 
LPS exposed cultures that was not significant. The apparent increase in active 
TGF-β2 following HDM SPT exposure could be explained by a concomitant 
increase in total TGF-β2. HDM SPT, scratch and LPS all resulted in increased 
TGF-β2 levels over control (Figure 4.13B). The relative levels of active TGF-β2 
are shown in Figure 4.13C. The percentage active TGF-β2 did not differ 
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significantly from control in any experimental challenge. This may be due to 
the wide variation seen in control unstimulated samples. 
 
Figure 4.13 TGF-β2 production by NHBEC donor 2F1578 24h following 
HDM challenge or injury. ALI cultures were challenged by HDM SPT (2000U),  
LPS (100ng/ml) or scratch injury. Media was collected at 24h for assay by ELISA 
shown as A. Active TGF-β2, B. Total TGF-β2 after heat-treatment of media and C. 
Percentage active TGF-β2.  Data were analysed by ANOVA followed by Tukey’s test 
(n=3, **p<0.01, ***p<0.005). 
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Figure 4.14 TGF-β2 production by NHBEC donor 7F3081 following HDM 
exposure or injury. ALI cultures were challenged by HDM SPT (2000U),  LPS 
(100ng/ml) or scratch injury. Media was collected at 24h for assay by ELISA shown as 
A. Active TGF-β2, B. Total TGF-β2 after heat-treatment of media and C. Percentage 
active TGF-β2.  Data were analysed by ANOVA followed by Tukey’s test (n=3, 
**p<0.01). 
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Primary cells from the final donor, 7F3000, were limited and only 3 
conditions were possible, taken at the 24h timepoint (Figure 4.15). There was 
wide variation in active TGF-β2 levels following HDM SPT, and also in control 
unstimulated samples. Scratch injury produced very little active TGF-β2. 
Results were not however statistically significant (Figure 4.15A).  
 
Differences in total TGF-β2 levels were not statistically significant due to wide 
variation and overlap between repeats and conditons. There was however an 
observable decrease in HDM SPT compared to control samples (Figure 4.15B).  
The proportion of active TGF-β2 present following challenge did not differ 
significantly across experimental conditions (Figure 4.15C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 Gaynor A. Campbell 
  108 
 
Figure 4.15 TGF-β2 production by NHBEC donor 7F3000 following HDM 
exposure or injury. ALI cultures were challenged by HDM SPT (2000U) or scratch 
injury. Media was collected at 24h for assay by ELISA shown as A. Active TGF-β2, B. 
Total TGF-β2 after heat-treatment of media and C. Percentage active TGF-β2.  Data 
were analysed by ANOVA followed by Tukey’s test (n=3, **p<0.01). 
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To determine the temporal pattern of TGF-β2 production and activation 
following HDM exposure or injury, ALI cultures were challenged and media 
collected for assay at earlier timepoints alongside the 24h timepoint. Two 
donors were available for this study: 2F1578 and 7F3081.  
 
The levels of active and total TGF-β2 produced at 1h, 4h and 24h post-
challenge by donor 2F1578 are shown in Figure 4.16A and 4.16B respectively. 
For active TGF-β2, control samples peaked at 4h, whereas HDM SPT exposed 
cultures displayed a continual increase. Low levels of active TGF-β2 were 
measured throughout the timecourse following LPS exposure, while scratch  
led to a 1h peak then drop at 4h before increasing to a level similar to control. 
All samples showed an increase in total TGF-β2 levels over time, regardless of 
experimental condition.  
 
Production of TGF-β2 by donor 7F3081 at 2h, 8h and 24h post-challenge is 
shown in Figure 4.17.  Active TGF-β2 levels in control samples were variable 
whilst HDM SPT exposure resulted in a peak 2h following challenge, and did 
not exceed control levels at 24h. Scratch injured levels fell between 8 and 24 
hours (Figure 4.17A). Active TGF-β2 production by NHBEC donor 7F3081 was 
disimilar to donor 2F1578. Total TGF-β2 production did not differ 
significantly between experimental groups in donor 7F3081 (Figure 4.17B), 
with the exception of HDM SPT exposure at 2h (p<0.05).  
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Figure 4. 16 Timecourse of TGF-β2 production by NHBEC donor 2F1578.  
ALI cultures were challenged by HDM SPT (2000U), LPS (100ng/ml) or scratch 
injury. Media was collected at 1, 4 and 24h for assay by ELISA shown as A. Active 
TGF-β2 and  B. Total TGF-β2 after heat-treatment of media (n=3 at each timepoint). 
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Figure 4. 17 Timecourse of TGF-β2 production by NHBEC donor 7F3081.  
ALI cultures were challenged by HDM SPT (2000U), LPS (100ng/ml) or scratch 
injury. Media was collected at 1, 4 and 24h for assay by ELISA shown as A. Active 
TGF-β2 and  B. Total TGF-β2 after heat-treatment of media (n=3 at each timepoint). 
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In all samples the majority of TGF-β2 was secreted by 1-2h, followed by a 
gradual accumulation. This may be due to the media change prior to challenge 
that removed any previously secreted soluble factors, inciting cells to replenish 
cytokine levels. Active TGF-β2 levels did not correlate well with total TGF-β2; 
the fluctuations in active TGF-β2 levels imply a complex and dynamic 
turnover in the presence of TGF-β responsive primary cells.  
 
Wide donor variability was apparent in this set of experiments. This was not 
unexpected, as donors are randomly acquired independent samples from the 
human population, and not a transformed cell line from a single source. They 
are a good model for respiratory research in this respect, as the irregularity in 
responses is indicative of responses amongst the wider population, but means 
that increased sample numbers are required to formulate an over-arching 
concept of normal cellular responses to challenge.  
 
The scope of donor variability was examined. Statistical analyses (one way 
ANOVA followed by Tukey test) were carried out between different donors for 
each challenge, with differences in active and total TGF-β2 levels shown in 
Figure 4.18A and 4.18B respectively. Scratch injured and LPS challenged 
samples showed statistically significant differences in active TGF-β2 levels 
between donors. Variation in control samples between donors is marked, and 
response to HDM extract also shows pronounced differences within and 
between donor samples. Active TGF-β levels were consistently variable across 
challenge types however, with total TGF-β2 appearing more regular. Total 
TGF-β2 levels (Figure 4.18B) were broadly consistent across the NHBEC 
donors. Only HDM extract challenge resulted in a statistically significant 
difference. The similarity in challenge response is especially surprising given 
the variation in control unstimulated cultures. This suggests that the 
injury/damage response is tightly regulated even in monotype culture with 
regard to LTGF-β2. Much greater variation was apparent in active TGF-β2 
levels. 
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Figure 4.18 Comparison of TGF-β2 production 24h post-challenge in 3 
independent NHBEC donors. ALI cultures were challenged by HDM SPT 
(2000U) LPS (100ng/ml) or scratch injury. Media was collected at 24h for assay by 
ELISA shown as A. Active TGF-β2 and B. Total TGF-β2 after heat-treatment of media. 
Data were analysed by ANOVA followed by Tukey’s test (n=3, *p<0.05). 
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4.4   Summary 
In this chapter, a house dust mite extract containing major allergens, used in 
skin prick testing (HDM SPT), and a preparation of lyophilised HDM spent 
culture matter (HDM FP) were shown to have detectable serine but not 
cysteine protease activity.  
 
HDM preparations did not directly activate native LTGF-β2 in a cell-free 
environment, although HDM FP partially degraded LTGF-β2 and TGF-β2 to a 
lesser extent than the archetypal cysteine protease papain.  
 
In the 16HBE14o- transformed cell line, HDM FP decreased both active and 
latent TGF-β2 levels, through proteolytic degradation of the cytokine and 
possibly other cell-mediated effects. HDM SPT decreased total TGF-β2 but 
had no significant effect on active cytokine levels. Plasmin and tryptase 
exposure increased total TGF-β2 levels, but the proportion of active cytokine 
was lowered by plasmin exposure. Scratch injury increased active and total 
TGF-β2 levels, in agreement with previously published work. 
 
Bronchial epithelial cells from healthy donors grown at ALI responded 
variably to HDM exposure and injury. Of 3 donors, one (2F1578) increased 
both active and total TGF-β2 levels following HDM SPT exposure.  
 
It was hypothesised that the proteolytic activity of HDM could activate latent 
TGF-β2 produced by human bronchial epithelial cells. From the results shown 
here, this was not apparent and so the hypothesis cannot be accepted.  
4.4 Discussion 
Allergen sensitisation is a contributing factor in up to 90% of asthmatic 
disease (Craig, 2010; Tovey et al., 1981). House dust mite (HDM) exposure is a 
known risk factor for the subsequent development of asthma (Platts-Mills et 
al., 1997; Sporik et al., 1992). Purified allergens from HDM have been used in 
some in-vitro studies to assess cellular responses to allergen challenge 
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(Kauffman et al., 2006; King et al., 1998), however an in-vivo study by Van 
der Veen et al. demonstrated that the asthmatic response was greater 
following exposure to a HDM extract than to purified Der p 1 or Der p 2 (Van 
Der Veen et al., 2001). This chapter aimed to identify whether HDM 
preparations could activate native latent TGF-β2 and whether HDM exposure 
led to increased expression of TGF-β2 by transformed and primary bronchial 
epithelial cells. TGF-β activation may be a multi-step proteolytic process, 
therefore this study utilised two HDM extracts containing a heterogenous mix 
of proteases. The HDM SPT extract is intended for clinical use in skin prick 
testing, and contains unspecified levels of major Dermatophagoides 
pterronysinus allergens. The HDM FP extract was derived from spent culture 
media of the Der p mite.  
 
The NBPVANA substrate had previously established protease activity of 
affinity-purified Der p 1 (Sehgal, 2005; Wan et al., 2000), and was cleaved 
here by the cysteine protease papain. However, cysteine protease activity was 
not detected in either HDM SPT or HDM FP using NBPVANA substrate. HDM 
SPT at 100,000U/ml contains around 9000ng/ml of total Der p protein 
(Rusznak et al., 2001), however specific levels of Der p 1 are unknown. The 
lack of cysteine protease activity could possibly be due to sensitivity of the 
assay in this case. HDM FP appeared to cleave both latent and active TGF-β2, 
and it is possible (although unlikely) that following solubilisation the protease 
mixture cleaved self proteins including Der p 1. Both preparations showed 
serine protease activity. HDM extracts can also contain collagenolytic (Der p 
9) and amylase-like (Der p 4) proteins, and may contain many more active 
substances (Thomas et al., 2002). The HDM preparations were not assayed for 
other protease classes. 
 
Latent TGF-β can be activated directly by proteolysis (Lyons et al., 1990; 
Oursler et al., 1993), although cell and/or matrix interactions may also be 
required (Abe et al., 1998; Sato et al., 1993). Nakamura et al. demonstrated 
activation of the small latent complex (SLC) of TGF-β1 in a cell-free system by 
the proteolytic action of purified Der f 1, an allergen from the North American 
Dermatophagoides farinae dust mite. Der p 1 and Der f 1 share 82% sequence 
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homology (Takai et al., 2005), so it may be supposed that Der p 1 has the 
potential to activate the SLC of TGF-β1. There are no similar studies of latent 
TGF-β2 activation.  
 
Results from TGF-β1 activation studies should not be directly extrapolated to 
TGF-β2. TGF-β1, -β2 & -β3 have 75% amino acid homology and share common 
receptors and signalling pathways. In contrast, their respective LAPs have 45-
50% amino acid homology, and can be further altered by glycosylation 
(Saharinen et al., 1999). LAP of TGF-β2 does not contain an RGD amino acid 
sequence and is therefore not thought to undergo integrin-mediated 
conformational or proteolytic activation. These differences may lead to 
differences in activation susceptibility, although the physicochemical 
activation profiles (via heat or acidification) of all three SLC isoforms are very 
similar (Brown et al., 1990). Activation by proteolysis is however more 
sensitive to sequence and structural differences that arise as these may affect 
enzyme recognition sites. Indeed, previous reports suggest that protease 
activation experimentally activates only 15-20% of the latent pool of TGF-β, 
but also degrades a proportion of the cytokine (Brown et al., 1990). 
Degradation of TGF-β2 by papain and HDM preparations was observed in 
cell-free and cell-associated experiments in this study. It should also be noted 
that no cell viability assays were carried out following protease exposure. It is 
therefore possible that decreases in TGF-β2 levels observed were due to 
decreased numbers of viable cells in the population. This could be ascertained 
through Annexin V staining of cultures, or trypan blue exclusion analysis of 
cell layers.  
 
The configuration of LTGF-β2 produced by bronchial structural cells is 
unknown. In the kidney, 5 different arrangements of latent TGF-β1 have been 
identified, and 3 in the prostate, due to secretion as either the SLC or large 
latent complex (LLC), and alternative splicing of LTBP proteins (Hyytiäinen et 
al., 2004). It would be of interest to determine the composition of latent TGF-
β2 complexes secreted by cells used in this study as these differences may be 
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important physiologically in determining the susceptibility of the latent 
cytokine to activation.  
 
The majority of cell types secrete TGF-β as a LLC, therefore removal of both 
LTBP and LAP to expose the receptor binding site of mature TGF-β2 is a 
requirement of activation. Cleavage of LTBP-1 in bone matrix secreted by 
osteoclasts has been identified through the proteolytic action of plasmin, 
elastase, MMP-2 and MMP-9 (Dallas, 2002). This freed the SLC for secondary 
steps of activation. Additionally, plasmin activation of TGF-β1 in the SLC was 
shown in a separate study to occur by proteolytic “nicking” of the latency-
associated peptide (LAP) (Lyons et al., 1988). Proteolytic processing of TGF-β 
from a latent to an active state can therefore occur via a multi-step process, 
and may involve multiple proteases.  
 
The serine protease tryptase is released by a a subset of mast cells upon 
degranulation. Tryptase-mediated activation of LTGF-β1 was previously 
shown by Tatler et al. in the presence of human airway smooth muscle cells 
(ASM), however total levels of TGF-β2 remained unchanged (Tatler et al., 
2008). In this study tryptase activated TGF-β2 in the presence of cells, and 
increased the total level of LTGF-β2 (Section 4.2.5). This discrepancy between 
results may be attributable to the use of a different cell type (ASM vs. 
transformed bronchial epithelial cells). Tryptase-mediated activation of cells 
provides a possible mechanism by which allergic asthmatics show increased 
epithelial TGF-β2 levels. 
 
Salib et al. investigated TGF-β production following HDM challenge (with a 
skin prick test formulation of HDM) of the nasal epithelial cell line RPMI 
2650, and found increased total TGF-β2. This is in contrast to the results from 
the transformed cell line 16HBE14o- reported here (Section 4.2.5). However, 
this may be due to differences arising from the use of transformed 
cells.Challenge with IL-4 or IL-13 did not alter TGF-β2 expression (Salib et al., 
2005). This is in contrast to data from primary HBEC challenge reported by 
Richter et al., whereby IL-4 and IL-13 exposure stimulated HBEC TGF-β2 
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release (Richter et al., 2001). This highlights the potential differences between 
transformed and primary cells, and  upper (nasal) and lower (bronchial) 
airway epithelial responses.  
 
The increase in active and total levels of TGF-β2, above that of physical injury, 
following HDM SPT challenge of a primary HBEC donor reported here is a 
novel finding. However, variability of primary cell responses means increased 
donor numbers are required for further investigations. 
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Chapter 5: TGF-β2 mediated remodelling responses of 
healthy and asthmatic bronchial fibroblasts 
 
5.1  Overview 
Chapter 3 demonstrated that mild asthmatic bronchial biopsy tissue had 
significant reticular basement membrane thickening and increased 
myofibroblast-like cells in the lamina propria. Chapter 4 established possible 
bronchial epithelial cell modulation of TGF-β2 secretion and activation linked 
to environmental challenge. Other authors have shown increased TGF-β2 in 
asthmatic tissue, both at baseline and following allergen challenge (Balzar et 
al., 2005a; Batra et al., 2004; Chu et al., 2004).  
 
It has been suggested that fibroblastic cells derived from asthmatic donors 
may show alterations at the level of morphology and baseline proliferation 
(Westergren-Thorsson et al., 2010). Increased collagen production has been 
identified in asthmatic lung, and linked with TGF-β1 expression and 
eosinophil infiltration (known secretors of TGF-β2 in the lung) (Nomura et al., 
2002). Previous publications by other groups using asthmatic fibroblasts 
demonstrated significant phenotypic changes using 500pg/ml TGF-β2 
(Thompson et al., 2006; Wicks et al., 2006). 
 
5.2   Aims & hypothesis 
This chapter addresses the  hypothesis that bronchial fibroblasts derived from 
mildly asthmatic donors are more sensitive to the pro-remodelling effects of 
TGF-β2 in comparison to healthy donor cells.  
The hypothesis will be tested through the following aims: 
1. Investigate alterations in ECM production following TGF-β2 exposure 
through pro-collagen Iα1 and pro-collagen III mRNA expression 
changes, and acid-soluble collagen protein measurements.  
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2. Evaluate myofibroblast differentiation by measurement of α-SMA 
expression levels.  
3. Evaluate non-contact communication from bronchial epithelial cells to 
underlying fibroblasts, by challenge of NHLF with HBEC conditioned 
media. ECM production and α-SMA changes will be monitored 
following challenge.  
 
5.3   Results 
5.3.1  Morphology and proliferation of primary bronchial 
fibroblasts from healthy and asthmatic donors 
The cells used in this study between passages 4-8 were grossly examined for 
alterations in appearance between healthy and asthmatic cells (Figure 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Primary healthy and asthmatic fibroblasts are morphologically 
indistinguishable in culture. Representative photomicrographs of healthy (A & 
C) and asthmatic (B & D)  fibroblasts. All donor cells showed the archetypal spindle 
shape of fibroblasts in culture. Positive staining (in green) for vimentin  (C & D, at 
x40 original magnification) confirmed a mesenchymal phenotype; nuclei are shown 
in blue (DAPI) (Scalebar = 50µm).  
 
 
 
 
C. D. 
B. A . 
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Gross examination of ongoing cultures did not reveal differences in cell 
phentoype. Mesenchymal cell type was confirmed by positive vimentin 
immunostaining.  There is no archetypal fibroblast protein marker, so instead 
cells were confirmed negative for desmin protein (smooth muscle marker), 
von Willebrand factor (endothelial marker) and cytokeratin (epithelial 
marker)(results not shown). Both healthy and asthmatic cells displayed the 
same marker expression profile. 
 
Initial assessment of fibroblast proliferation was carried out following 48h in 
culture with and without TGF-β2 (Figure 5.2). A preliminary experiment using 
1, 5 and 10ng/ml TGF-β2 showed the lower limit of 1ng/ml TGF-β2 was 
sufficient to increase collagen protein production. Previous publications by 
other groups using asthmatic fibroblasts demonstrated significant phenotypic 
changes using 500pg/ml TGF-β2 (Thompson et al., 2006; Wicks et al., 2006). 
In addition, NHBEC were shown to secrete up to 600pg/ml total TGF-β2 in 
the previous chapter (Section 4.2.6). For all fibroblast stimulations it was 
decided to use 1ng/ml as standard. 
 
Assessment of proliferation rate was carried out 48h after seeding in 12 well 
plates, with and without TGF-β2. Results are shown as proliferation rate 
(Figure 5.2). Baseline fibroblast proliferation did not differ between healthy 
and asthmatic donor cells used in this study. TGF-β2 exposure led to a 
decrease in proliferation, more apparent in healthy samples tested.  
 
Donor cells used in this study showed no significant increases in cell 
morphology, baseline proliferation or proliferative response to TGF-β2.  
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Figure 5.2 Fibroblast proliferation in-vitro following TGF-β2 stimulation 
No significant difference in proliferation was observed following 1ng/ml TGF-β2 
exposure for 48h, or between healthy and asthmatic cell basal or TGF-β2 stimulated 
rates. (2 subjects/group; n=6 for each subject). Data is expressed as % fibroblast 
proliferation (cell no. at 48h/(initial seeding cell no./100). 
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5.3.2  Timecourse gene expression analyses  
Quantitative PCR (q-PCR) was used to determine the expression of COLIα1 
(pro-collagen Iα1), α-SMA and TGF-β2 in healthy NHLF over time. The 
expression pattern of these genes thought to be upregulated in asthma and 
following TGF-β2 stimulation. mRNA was extracted at timepoints between 0 
and 72h. Cells were between 70-80% confluency at 0h to avoid contact 
inhibition affecting mRNA transcription. Gene expression results were 
normalised to GAPDH and ATP5B, and shown as a fold change from baseline 
expression at timepoint 0h (Figure 5.4). Results were analysed by one-way 
ANOVA, followed by Dunnett’s post-hoc test comparing values to that of the 
time zero control. 
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Figure 5.3 Timecourse of mRNA expression levels in NHLF following 
TGF-β2 stimulation. Fibroblast cultures were stimulated with 1ng/ml TGF-β2, 
mRNA harvested and reverse transcribed, then q-PCR analysis of A. COLIα1, B. α-
SMA and C. TGF-β2 performed. Values were normalised to GAPDH and ATP5B,  and 
are shown as a fold change from time zero, +/- SEM. n=5 independent samples at 
each timepoint. Data analysis showed no statistical significance. 
 Gaynor A. Campbell 
  126 
Expression of COLIα1 was variable over the timecourse, showing greatest 
increases at 24h and 48h after stimulation. At 72h following stimulation 
cultures had become quiescent and did not yield sufficient RNA for analysis. 
Up to 48h, fold change increases in COLIα1 expression were consistently 
observed, but did not show statistical significance were statistically 
insignificant due to wide variation within each timepoint.  
 
α-smooth muscle actin mRNA expression was nominally greatest 6h following 
stimulation, however variation within the sample group meant it was not 
significant. At 24h, there was a consistent trend towards increased α-SMA 
expression, that fell to below baseline levels by 48h. TGF-β2 expression was 
marginally increased over the timecourse, but again showed wide within-
timepoint variability, and was not statistically significant.  
 
In the healthy bronchial fibroblasts used results were not statistically 
significant, however increases in expression were observed at 24h for the three 
genes analysed. Pro-collagen Iα1 showed greatest increases following TGF-β2 
exposure. This timepoint was used in all further q-PCR analyses.  
 
5.3.3 Comparison of collagen production by healthy and asthmatic 
bronchial fibroblasts in culture  
The previous section established that 24h was an optimal timepoint for mRNA 
analyses using commercially obtained healthy fibroblasts. In the following set 
of experiments, fibroblasts isolated from 1 healthy and 2 mildly asthmatic 
donors were challenged with TGF-β2 at 1ng/ml. Cultures were harvested at 
24h, mRNA extracted and reverse transcribed, and q-PCR performed (Figure 
5.5). Only one healthy donor sample was available for qPCR analysis due to 
limited sample availability.  
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Figure 5.4 mRNA expression levels of COLIα1 (A) and COLIII (B) in 
healthy and asthmatic fibroblasts at 24h post TGF-β2 stimulation. mRNA 
was harvested 24h after challenge with 1ng/ml TGF-β2. mRNA levels are expressed 
relative to GAPDH and ATP5B, and as a fold change from time-matched unstimulated 
controls. ** p=<0.01. N=3 for each subject.  
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Pro-collagen Iα1 expression was increased in all samples following 24h TGF-
β2 exposure. There was a significant increase in COLIα1  between asthmatic 
sample 2 and healthy, and between asthmatic sample 2 and asthmatic sample 
1. Greatest increases from time matched controls were observed in healthy 
fibroblasts. Results here suggest that the 2 asthmatic fibroblast samples  
assessed did not have an increased TGF-β2 initiated collagen response 
compared with healthy fibroblasts. 
 
The mRNA levels indicate up- or downregulation of the gene, but not the 
successful secretion of the protein. Determination of collagen protein 
production in-vitro in this study was by SircolTM assay. This contains Sirius 
red dye that binds to the Gly-X-Y helical structure of mammalian collagen 
fibrils types I-V. It does not detect mature fibrils of covalently cross-linked 
collagen without prior acid-pepsin digestion, and so measured only newly 
synthesised collagen. To gauge complete collagen production, both soluble 
secreted levels in conditioned media and cell layer-associated collagen were 
measured in 2 healthy and 2 asthmatic-derived fibroblast donors. The results 
were normalised to cell number (Figure 5.6). 
 
Results illustrate increased total (media + cell layer) collagen protein 
production within each donor cell set. Figure 5.6A shows a significant 
response (p<0.001) to TGF-β2 stimulation by a healthy donor, whilst the 
healthy donor 2 in Figure 5.6B did not reach statistical significance. Both 
asthmatic donor samples 1 and 2 significantly increased collagen production 
when exposed to TGF-β2 (p<0.05). To assess whether these changes were 
significantly different between groups, collagen protein levels were converted 
to percentage increases (Figure 5.7). 
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Figure 5.5 Analysis of total collagen secretion at 48h in healthy and 
asthmatic fibroblasts, with and without  TGF-β2 stimulation.  
Total collagen produced by healthy (A & B) and asthmatic (C & D) fibroblasts, 48h 
following TGF-β2 stimulation, in the presence of L-proline and ascorbic acid. 
Collagen production is shown normalised to cell number. Within donor data 
(stimulated vs. unstimulated) were analysed by t-test. *p<0.05, n=5 for each donor 
and condition.  
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Figure 5.6 Percentage collagen production increase following  TGF-β2 
stimulation. Results were analysed by ANOVA followed by Dunnett’s test.  
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Collagen protein production was variable both within and between donors. 
Healthy donor 1 showed a significant increase (p<0.05) in % collagen 
production compared with healthy donor 2 and asthmatic donor 1 fibroblasts.  
 
In the preceding results, no difference was attributable to the asthmatic status 
of cells. It was shown that primary cell responses are highly variable, and no  
distinction can be made between mildly asthmatic and healthy fibroblast 
collagen production. This is in agreement with previously published studies 
(Dubé et al., 1998). 
 
5.3.4 Comparison of myofibroblast differentiation in healthy and 
asthmatic bronchial fibroblasts in culture 
Differentiation of the bronchial fibroblast to a more secretory, smooth muscle-
like cell type – the myofibroblast, may be an important facilitator of AWR 
phenomena.  Conventionally this differentiation is identified by the expression 
of α-smooth muscle actin (Darby et al., 1990), and may be increased in allergic 
asthma (Gizycki et al., 1997). TGF-β2 stimulated  and control fibroblasts were 
harvested for mRNA and protein, and α-smooth muscle actin expression and 
production analysed.  
 
Asthmatic donor samples (n=2) showed a significant increase in α-SMA 
mRNA compared to healthy fibroblasts at 24h. Similar results were reported 
by Wicks et al., who also showed asthmatic fibroblasts responded with smooth 
muscle transcript increase at a ten-fold lower concentration of TGF-β2 than 
healthy (Wicks et al., 2006).  
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Figure 5.7 Expression level of  α-SMA mRNA in healthy and asthmatic 
fibroblasts 24h following TGF-β2 stimulation.  mRNA levels are expressed 
relative to GAPDH and ATP5B, and as a fold change from time-matched controls +/- 
SEM. *p<0.05, **p<001, n=3 for each subject. ANOVA followed by Tukey’s. 
 
For protein analysis, initially 24h, 48h and 72h timepoints were assayed and 
48h chosen as most representative timepoint. One healthy and one asthmatic 
donor were available for assay due to limited sample availability. TGF-β2 
challenge experiments were repeated three times in each set of donor 
fibroblasts.  
 
Fibroblast cultures were harvested at 48h in RIPA buffer, cell lysates 
seperated on 4-12% gradient SDS-PAGE gels and blotted onto nitrocellulose 
membrane. Membranes were probed for α-SMA protein. To ensure equal 
loading of gels and to normalise α-SMA band densities, membranes were 
stripped and re-probed for vimentin. Results from healthy donor fibroblasts 
are shown in Figure 5.9. α-SMA protein levels did not differ significantly from 
control at 48h. TGF-β2 challenge was repeated on one set of asthmatic donor 
fibroblasts (Figure 5.10). 
 
 
 
 Gaynor A. Campbell 
  133 
 
 
 
    A. 
B.  
 
 
       1     2        3      1       2       3  
Control       + TGF-β2 
 
Figure 5.8 Healthy fibroblast α-SMA protein expression. 
Relative optical density of western blotted α-SMA protein bands were measured on ?? 
(A). A representative scanned image of α-SMA is shown in (B). α-SMA was 
normalised to vimentin expression. No significant difference was found (n=3). 
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   A. 
B.  
 
      C. 
 
           1   2       3        1       2       3  
         Control                + TGF-β2 
 
Figure 5.9 Asthmatic fibroblast α-SMA protein expression.  
Band densitometry (A)  shows significant increase in α-SMA protein (+/- SEM, 
analysed by t-test, p<0.001). Representative α-SMA protein bands shown in (B) were 
measured and normalised to vimentin levels (C) (n=3). 
 
As seen in Figure 5.10B, α-SMA was consistently increased following TGF-β2 
stimulation in asthmatic fibroblasts from one donor. This is consistent with 
qPCR results shown in Figure 5.8. Baseline protein expression did not differ 
between healthy and asthmatic donors.  A conclusion cannot be drawn from 
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these results as to whether asthmatic cells are intrinsically more sensitive to 
TGF-β2, due to insufficient donor sample number. Results do confirm 
however, the variability inherent in primary cell responses.   
 
5.3.5   Healthy bronchial fibroblast remodelling responses 
modulated by HBEC soluble secreted factors 
As the barrier between underlying lung tissue and the environment, bronchial 
epithelial cells are thought to respond to environmental challenge with a 
cascade of  actions that could affect many underlying cells including bronchial 
fibroblasts. In Chapter 4 Section 4.2.6 it was shown that TGF-β2 secretion can 
be modulated in HBEC in reponse to environmental challenge. The following 
section addresses the hypothesis that healthy bronchial fibroblasts would 
show increased remodelling responses (collagen production and myofibroblast 
differentiation) when exposed to soluble secreted factors present in bronchial 
epithelial cell conditoned media. It was also posited that exposure to 
conditioned media derived from asthmatic bronchial epithelial cells would 
generate a greater response.  
 
5.3.5.1  HBEC conditioned media effects on ECM production by 
healthy fibroblasts 
Bronchial epithelial cell conditioned media was prepared by collecting from 
healthy and asthmatic HBEC cultures between d7-21 of ALI culture. Media 
from single donors was pooled and frozen at -20°C until use. Control 
fibroblast cultures were exposed to fresh BEDM, and challenged cultures 
received half fresh BEDM, half HBEC conditioned BEDM. Only healthy 
fibroblasts were challenged in these experiments.  
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Figure 5.10 mRNA expression levels of COLIα1 in healthy fibroblasts at 
24h. Cultures were exposed to BEDM (control) or 50% healthy bronchial epithelial 
cell conditioned media (HCM). mRNA levels are expressed relative to the geometric 
mean of GAPDH and ATP5B. No significant difference was found (n=2). 
 
 
Figure 5.11 Total collagen secretion by healthy fibroblasts following 
conditioned medium exposure. Healthy (HCM) and asthmatic (ACM) HBEC CM 
exposed fibroblast cultures were analysed by Sircol assay at 48h.Results are shown 
normalised to cell number. Results were analysed by ANOVA followed by Dunnett’s 
post-hoc test. (*p<0.05, **p<0.01, n=5). 
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No difference was observed in pro-collagen Iα1 mRNA expression in healthy 
fibroblasts following healthy BEC conditioned media exposure (Figure 5.11). 
Insufficient asthmatic conditioned media was available at the time of the 
experiments, and so was not included.  Exposure to HBEC CM significantly 
increased healthy fibroblast collagen protein production compared with 
control BEDM alone (Figure 5.12). Asthmatic-derived CM exposure had an 
even greater effect than healthy CM.  
 
Asthmatic CM was  assayed by ELISA at 1036pg/ml total TGF-β2, and 
34.3pg/ml active TGF-β2, in comparison to healthy CM that had 1191pg/ml 
total TGF-β2 and 16.3pg/ml active. As the active (and therefore available) 
TGF-β2 levels are so low, it is highly likely that other secreted factors are 
affecting collagen production.  
 
5.3.5.2  HBEC conditioned media effects on myofibroblast 
differentiation by healthy bronchial fibroblasts 
α-SMA protein expression was assessed as an indicator of myofibroblast 
differentiation following conditioned media exposure. HBEC CM exposure 
significantly increased healthy fibroblast α-SMA production compared with 
control media (Figure 5.10). As with collagen protein production, asthmatic-
derived CM exposure had an even greater effect than healthy CM. 
 
Results suggest that in the asthmatic CM used, there is either an increase in 
one factor that can drive collagen production and myofibroblast 
differentiation, or that a combination of soluble factor alterations are having a 
direct effect on fibroblast phenotype and function, that could then contribute 
to AWR. 
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Figure 5.12 Healthy fibroblast α-SMA protein expression following 48h 
conditioned media exposure. Healthy (HCM) and asthmatic (ACM) HBEC CM 
exposed fibroblast cell lysates were western blotted. Band densitometry showed 
variable yet significant (p<0.01)  increases in α-SMA protein expression. Results were 
analysed by ANOVA followed by Dunnett’s test (n=3). 
 
5.3  Summary 
Fibroblasts isolated from healthy and asthmatic donors appeared 
phenotypically similar. All donor cells responded to TGF-β2 stimulation. 
 
Collagen mRNA and protein levels varied between donors. TGF-β2 stimulation 
resulted in increased expression and protein production, but this did not differ 
significantly between healthy and asthmatic donor fibroblasts. A significant 
increase in α-SMA mRNA was observed following TGF-β2 stimulation in both 
healthy and asthmatic donor cells. Asthmatic cells showed a statistically 
greater increase than healthy cells, and this was also shown at the α-SMA 
protein level.   
 
Conditioned media derived from asthmatic HBEC had a greater effect upon 
collagen production and α-SMA by NHLF than healthy HBEC CM, and was 
not attributable solely to TGF-β2 levels. 
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The aims of this chapter were conceived to test the hypothesis that bronchial 
fibroblasts derived from mildly asthmatic donors are more sensitive to the 
pro-remodelling effects of TGF-β2 in comparison to healthy donor cells. 
Experimental results showed α-SMA expression was increased in asthmatic-
derived fibroblasts to a greater degree than in healthy fibroblasts. In the 
limited sample sizes used, the hypothesis may be partially accepted; asthmatic 
fibroblasts were more susceptible to the pro-myofibroblast differentiation 
effect of TGF-β2, but not to the pro-secretory effects.  
 
5.4  Discussion 
There is a wealth of published literature that attempts to identify intrinsic 
differences in asthmatic structural cells, often employing in-vitro studies. 
There appears no consensus as to whether mildly asthmatic fibroblasts are 
morphologically distinct from their healthy counterparts. Kotaru et al. 
assessed fibroblasts from bronchial and distal regions of asthmatic lung, and 
asserted that increased cytoplasmic projections on bronchial fibroblasts was 
indicative of a resident secretory cell type, rather than a more spindle-shaped 
proliferative phenotype (Kotaru, 2006). This study did not compare asthmatic 
derived cells with healthy controls however. Nihlberg et al. used this method 
to compare healthy and mildly asthmatic cells in the same manner, finding 
that asthmatic bronchial fibroblasts had significantly (1.4x, p<0.001) more 
extensions than healthy. This was taken by the authors to indicate an ECM 
secretory phenotype (Nihlberg et al., 2010). This method was not used in this 
study as it relatively untried.  
 
The Nihlberg study above described baseline proliferation as 24% lower in 
mildly  asthmatic fibroblasts, which disagrees with the finding shown in Figure 
5.2. Other studies have found increased proliferative rates in asthma, although 
their results are taken following stimulation with the Th2 cytokines IL-4 and 
Il-13 (Kraft et al., 2001). However, the results presented here, finding no 
significant difference between healthy and asthmatic cells, are in agreement 
with other authors (Ward et al., 2008). These contrasting results may be due 
to differences in cell passage number, or confluence prior to seeding making 
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cells more quiescent and therefore increasing time taken to enter the cell 
growth cycle. Additionally, these reports use different methods to calculate 
proliferation, including MTT assay, crystal violet absorbance and cell counts.  
 
Validation of the stability of expression of housekeeping genes is an important  
pre-requisite of q-PCR studies as results may otherwise be misleading. The 
geNormTM analysis shown in Figure 5.3 was undertaken following  publication 
of an increase in expression of commonly used housekeeping genes in 
bronchial fibroblasts exposed to TGF-β2 (Wicks et al., 2006). Furthermore, 
the authors reported a 10-fold lower threshold of smooth muscle-related gene 
transcript activation in asthmatic fibroblasts, a result which broadly in 
agreement with the finding of this study that asthmatic cells were more 
predisposed to increase α-SMA protein production upon TGF-β2 stimulation.  
 
Increased collagen production in asthmatic lung was previously demonstrated 
by measurement of collagen peptides in induced sputum of asthmatics 
(Nomura et al., 2002). Other studies have used analysis of amino acid 
hydroxyproline levels by HPLC to determine collagen deposition in-vivo and 
in-vitro (Marshall et al., 2004), however the SircolTM assay is now a well-
validated and reproducible method of collagen measurement. Dube et al. 
compared baseline pro-collagen I and III production by healthy and asthmatic 
bronchial fibroblasts, and reported no difference between diseased and control 
cells. The authors did not assess collagen production following TGF-β isoform 
stimulation (Dubé et al., 1998). A study using fibroblasts isolated from lung 
resection tissue did not find a significant increase in collagen I or collagen III 
mRNA or protein following TGF-β2 or TGF-β1 stimulation (Batra et al., 2004). 
This could be attributable to fibroblast source, as cells were isolated from lung 
parenchyma and not bronchial tissue. Contrastingly, Malavia et al. reported 
TGF-β2 derived from HBECs stimulated soluble collagen production by NHLF 
as measured by SircolTM , a finding repeated in this study (Malavia et al., 
2008).  Alteration in MMP:TIMP levels is another mechanism by which 
collagen homeostasis may be altered in the asthmatic lung (Cataldo et al., 
2004), and it was reported that asthmatic bronchial fibroblasts in culture 
exhibited a decreased capacity to degrade collagen, through decreased 
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production of MMP-2, than healthy control fibroblasts (Laliberté et al., 2001). 
Subepithelial collagen deposition is a feature of AWR thought attributable to 
increased numbers of myofibroblasts in the lamina propria (Zhang et al., 
1994). 
 
During myofibroblast differentiation cells generate an intra-cellular 
contractile apparatus containing microfilaments of α-SMA, and other smooth 
muscle related proteins. In a study comparing asthmatic and healthy bronchial 
fibroblast responses to TGF-β2, Wicks et al. showed increased α-SMA mRNA 
and protein expression in both cell types. Asthmatic cell α-SMA expression 
was not significantly greater than healthy, however expression of the smooth 
muscle related protein calponin 1 was higher in asthmatic fibroblasts. This 
work also showed asthmatic fibroblasts to be maximally responsive to TGF-β2 
at a 10-fold lesser concentration than healthy fibroblasts (500pg/ml vs. 
5ng/ml) (Wicks et al., 2006).  Similar α-SMA expression results with a single 
(1ng/ml) concentration of TGF-β2 were reported here, and subsequently it 
may be of interest to challenge healthy and asthmatic fibroblasts with a range 
of TGF-β2 concentrations for a more informative comparison of TGF-β2 
responsiveness.  
  
Bronchial epithelial cells have been shown to secrete increased amounts of 
TGF-β2 following injury, and TGF-β2 is increased in asthmatic tissue and BAL 
fluid (Balzar et al., 2005a; Thompson et al., 2006; Zhang et al., 1999). 
Exposure of fibroblasts to bronchial epithelial cells or conditioned medium 
has been used to investigate cellular responses, and here produced increases in 
collagen production and α-SMA expression that were greater than TGF-β2 
levels alone could account for. These results suggest that in the HBEC CM 
used, there is altered secretion of a soluble factor or factors that drive collagen 
production and myofibroblast differentiation, and so subsequently contribute 
to AWR. These alterations appear more pronounced in cells challenged with 
asthmatic HBEC CM than healthy HBEC CM. Identification of this activity 
could begin by fractionation of conditioned media by molecular weight prior to 
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fibroblast challenge to establish those weight fractions that produce the 
greatest increases in the chosen remodelling markers. 
 
Previous work by other groups has identified a number of soluble secreted 
factors from HBECs that affected bronchial fibroblast remodelling responses. 
Hastie et al. reported that asthmatic epithelial cell CM stimulated collagen III 
production, but not collagen I by fibroblasts (Hastie et al., 2002). In this 
Chapter, it was reported that the ColIII gene was lowly expressed and highly 
variable. Individual collagen subtypes were not assayed, instead the SircolTM 
assay used measured soluble collagens I-V, and so any increase in collagen III 
will be represented in the results given. A co-culture model of fibroblasts cast 
in type I collagen gels floating above a submerged monolayer of HBECs 
identified TGF-β2 production by HBECs as the causative factor leading to 
increased gel contraction. Similar results were reported with HBEC CM alone. 
Of note, contraction was further increased when HBEC cells were exposed to 
LPS (Mio et al., 1998). TLR-4 activation via LPS and Der p 2 is seen following 
HDM stimulation of cells. In Chapter 4, Section 4.2.6, it was shown that LPS 
exposure increased active TGF-β2 significantly in one of two primary HBEC 
donors challenged. Additionally, connective tissue growth factor (CTGF), a 
known downstream effector of TGF-β, could have been secreted by HBECs 
following autocrine TGF-β signalling and thereby increased fibroblast collagen 
production as seen (Nishioka et al., 2011).  
 
Several studies report HBEC control of fibroblast proliferative responses. Xu 
et al. reported that MMP-2 was secreted by HBECs and induced bronchial 
fibroblast proliferation (Xu et al., 2002), whilst McAnulty et al. identified 
modulation by bronchial epithelial prostaglandin E2 (PGE2) production . 
Furthermore, proliferation was increased in a study by Matsushima et al. 
showing human airway trypsin-like protease (HAT) produced by HBECs 
activated PAR-2 on bronchial fibroblasts (Matsushima et al., 2006). Following 
injury of 16HBE14o- cells, increased levels of TGF-β2, basic Fibroblast Growth 
Factor (b-FGF), platelet-derived growth factor (PDGF) and endothelin-1 levels 
were assayed in culture supernatants (Zhang et al., 1999). Exposure of 
fibroblasts to this CM increased proliferation significantly, and blocking these 
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growth factors inhibited fibroblast proliferation by 76%. Remodelling markers 
were not assessed however. 
 
Finally, of relevance to the in-vitro culture system used TβR expression can be 
affected in-vitro by cell density, with a low cell density maintaining high 
receptor levels and an enhanced response to TGF-β stimulation in comparison 
to high cell density cultures (Petridou et al., 2000; Raghu et al., 1989). 
Although cultures were time-matched, it is possible that small differences in 
confluency could have affcted the capacity of cells to respond to TGF-β2. 
Additionally, assessing cells in-vitro separate from the inflammatory context 
of the asthmatic airway could affect TGF-β responsiveness, suggested by the 
finding that GM-CSF stimulation increased expression of TGF-β receptors 
TβRI, TβRII and TβRIII on airway smooth muscle cells (Chen et al., 2003). 
 
Assessment of fibroblast responses made in complete isolation can provide 
insight into remodelling mechanisms, however the conditioned media 
challenge results confirm that crosstalk via soluble mediators between cell 
types is important in mediating cellular behaviour. Furthermore, fibroblasts 
can influence epithelial cell behaviour, shown by fibroblast CM challenge of 
bovine bronchial epithelial cells causing a proliferative response, attributed to 
fibroblast production of hepatocyte growth factor (Skibinski et al., 2007). 
Evidence presented here and from accumulated published data suggests a role 
for TGF-β2 produced by HBEC in driving the responses of underlying 
fibroblasts, although other mediators act alongside the cytokine to produce the 
sub-epithelial fibrosis of airway wall remodelling.  
 
5.5  Future Work 
The work presented in this thesis aimed to test whether alterations in active 
TGF-β2 levels contribute to airway wall remodelling in the asthmatic lung. 
Some progress was made towards this, however several points remain upon 
which this hypothesis may be further tested.  
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Improvements to the assessement of TGF-β2 protein expression in biopsy 
tissue could be made through use of a fluorescently labelled secondary 
antibody.   Subsequent measurement of fluorescent counts in a defined area of 
tissue rather than the more subjective scoring method employed in this study 
could yield more confident grading of TGF-β2 expression. Additionally, TGF-β 
activity (rather than protein) could be enumerated by intracellular staining of 
the downstream signalling protein, phospho-Smad 2.  
 
In TGF-β activation studies, phospho-Smad2 levels could be analysed by 
western blot of cell lysates, indicating whether TGF-β2 was activated and 
signalled within a short time frame not observable via ELISA of conditioned 
media. The HDM FP preparation could be fractionated into serine and 
cysteine proteinase fractions according to the protocol of Winton et al. 
(Winton et al., 1998), and used individually in cell challenges. 
 
This study examined tissue and cellular responses from mild, steriod naïve 
atopic asthmatics vs. non-atopic healthy controls. Inclding new sample groups 
of non-atopic asthmatics and atopic healthy controls could provide 
information about basal TGF-β2 regulation in an atopy as well as allergy. Most 
importantly, the study could be extended to include to include cells and tissue 
from moderate/severe asthmatics. Phenotypic differences between healthy 
and severely diseased cells are potentially larger, and therefore more easily 
identifiable. This could be of use in future experiments seeking to modulate 
the TGF-β2 response.  
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Appendix A 
Preparation of solutions and protocols for histology (all adapted from “Theory 
and Practice of Histological Techniques, Bancroft & Stevens, 1990). 
 
D.1 Haematoxylin and Eosin stain 
The basic dye haematoxylin stains acidic structures a purple-blue. Nuclei, 
ribosomes and rough endoplasmic reticulum have a strong affinity for this dye 
due to high content of DNA and RNA respectively. Eosin is an acidic dye which 
stains basic structures pink to pink-red. 
 
Harris’ Haematoxylin 
Haematoxylin monohydrate   5g 
Aluminium potassium sulphate 12 hydrate 85g 
100% alcohol (IMS)     50ml 
Glacial acetic acid     40ml 
Sodium iodate     1g 
dH2O       900ml 
 
Eosin 
Eosin y      5g 
dH2O       500ml 
 
Protocol 
1. Filtered Harris’ haematoxylin   4 minutes 
2. Running water to “blue”    5 minutes 
3. Eosin      30 seconds 
4. Brief rinse in water 
5. Dehydrate through increasing concentrations of alcohol, to xylene ready for 
mounting. 
 
D.2 Masson’s Trichrome  
Nuclei and other basophilic structures are stained blue, collagen green and 
cytoplasm and erythrocytes red.  
 
Weak picric acid (1% picric acid in 70% alcohol) 
Picric acid      6g 
100% alcohol (IMS)     350ml 
dH2O       150ml 
 
Biebrich scarlet (0.1%) 
Biebrich scarlet     0.5g 
Glacial acetic acid     5ml 
dH2O       500ml 
 
2.5% phosphomolybdic acid (PMA)/ 2.5% phosphotungstic acid 
(PTA) 
Phosphomolybdic acid    12.5g 
Phosphotungstic acid    12.5g 
dH2O       500ml 
Acids seperately dissolved in 250ml dH2O, then two solutions combined.  
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Fast green (2.5% fast green in 2.5% acetic acid) 
Fast green      12.5g 
Glacial acetic acid     12.5ml 
dH2O       487.5ml 
 
1. Harris’ haematoxylin    4 minutes 
2. Running water to “blue”    5 minutes 
3. 1% Picric acid     30 seconds 
4. Running water until faint yellow tint remains 
5. 0.1% Biebrich scarlet    1 minute 
6. Brief rinse in water 
7. 50% PMA/PTA     10minutes 
8. Fast green      6 minutes 
9. Dehydrate through increasing alcohols, to xylene ready for mounting.  
 
D.3 Periodic acid-Schiff’s (PAS) 
Stains glycogen and other reactive carbohydrates magenta, and nuclei blue.  
All stocks are bought from Sigma Aldrich, Dorset at ready to use 
concentrations. 
 
1. 1% periodic acid     10 minutes 
2. Rinse in running water    2 minutes 
3. Schiff’s reagent     10 minutes  
4. Rinse in running water    5 minutes 
5. Harris’ haematoxylin    2 minutes 
6. Dehydrate through increasing alcohols, to xylene ready for mounting.  
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